>>WELCOME
HERE IN BUFFALO NEW
YORK, THE SUN IS SHINING TODAY.
THAT'S NOT ALWAYS BEEN THE CASE.
THIS WINTER WE'VE HAD A LOT OF
SNOW AND BAD WEATHER AND SO
HOPEFULLY THINGS ARE GOOD WHERE
ALL OF YOU ARE.
I FIRST WANT TO REMIND THE
COMMITTEE AND ESPECIALLY THE
COMMITTEE MEMBERS THAT YOU MUST
ABSTAIN OR MAKE IT KNOWN, DURING
SPECIFIC DISCUSSIONS, WHEN YOU
ARE PARTICIPATING IN
DELIBERATIONS, ON A PARTICULAR
PRODUCT, PROGRAMMES, OR SPECIFIC
MATTER THAT WOULD CONSTITUTE A
CONFLICT OCONFLICT OF INTEREST.
WE KNOW WHEN IT'S NOT FEELING
RIGHT AND YOU ARE IN CONFLICT.
IF THAT'S THE CASE, IT'S
INCUMBENT UPON YOU TO ADVISE OUR
EXECUTIVE SECRETARY, AND TO
ABSTAIN FROM ANY PARTICIPATION
IF THAT DISCUSSION OR ACTION
REGARDING THAT MATTER.
IN KEEPING WITH THE CURRENT
POLICY, GOVERNING CONFLICT OF
INTEREST, BASED ON FINANCIAL
HOLDINGS OF SPECIAL GOVERNMENT
EMPLOYEES, WHICH CATEGORY
INCLUDES ALL MEMBERS OF THIS
COMMITTEE, WE MUST DEPEND ON YOU
TO IDENTIFY YOURSELF DURING ALL
THE DISCUSSIONS OR MATTERS THAT
COULD IMPACT THE STATUS OF THESE
PROCEEDINGS AND HOLDINGS.
AND IT'S IMPORTANT IF YOU HAVE A
REFRESHER.
IF YOU HAVE ANY ITEMS THAT YOU
WOULD LIKE TO REPORT, PLEASE LET
US KNOW.
MEMBERS OF THE PUBLIC WHO WISH
TO DISCUSS VIEWS DURING TODAY'S
MEETING, MAY DO SO IN WRITING TO
DrTHE EXECUTIVE SECRETARY WITHIN
10 DAYS OF THE MEETING AND ANY
WRITTEN STATEMENTS BY THE
MEMBERS OF THE PUBLIC WILL
RECEIVE CAREFUL CONSIDERATION.
BY-LAW, A QUORUM OF COMMITTEE
MEMBERS IS REQUIRED FOR EACH
INSTANCE AND DURING TODAY'S
MEETING, SEVEN APPOINTED MEMBERS
MUST BE PRESENT TO BOAST THEIR
VOICE SINCE WE CONDITION PRO
DICTIONARY THE TIME OR
OCCURRENCE OF ANY MOTION AND
YOUR PRESENCE IS A MUST FOR ALL
SEGMENTS OF THE MEETING.
AND I BELIEVE WE DON'T HAVE A
QUORUM RIGHT NOW SO I THINK
WE'RE GOING TO --
>> WE DO?
>> PERFECT!
PERFECT.
SO, HOPEFULLY YOU ALL HAVE
LOOKED AT THE MINUTES THAT WERE
IN YOUR PACKAGE.
AND DO I HAVE A MOTION TO
APPROVE THE MINUTES FROM THE
LAST FNLAC MEETING HELD ON
OCTOBER 18th, 2021?
>> I MOVE.
>> THANK YOU.
A SECOND?
>> THANK YOU.
ANY COMMENTS?
ANY DISCUSSION?
>> IT WAS ON PAGE 6 AND YOU
MEANT TO SAY.
>> YEAH, VERY GOOD PICK UP.
ANYTHING ELSE?
>> BY ANYONE.
>> SO ALL THOSE IN FAVOUR I,
HOLD YOUR HANDS UP.
ANYONE OPPOSED.
ABSTAINED?
ALL RIGHT.
THANK YOU VERY MUCH.
>> I ALSO WANT TO MAKE A NOTE OF
THE FUTURE MEETING DATES THAT
ARE LISTED IN THE AGENDA THEY
WERE CONFIRMED AT THE
OCTOBER 2021 MEETING AS NOTED IN
THE MINUTES AND SO A LIST OF THE
CONFIRMED FUTURE MEETINGS IS ON
THIS AGENDA AND OUR NEXT MEETING
WILL BE A VIRTUAL MEETING IN
JUNE AND 27th TO THE 28th,
2022, MARK YOUR CALENDERS
ACCORDINGLY.
THIS IS A VIRTUAL MEETING.
SO, WITHOUT ANY FURTHER ADIEU,
OF ALL THE ANNOUNCEMENTS, OUR
FIRST AGENDA ITEM IS ONE WE ALL
LOOK FORWARD TO IS OUR NCI
DIRECTOR'S REPORT FROM Dr. NED
SHARPLESS.
>> GREAT, GOOD AFTERNOON.
IT'S GOOD TO SEE EVERYONE
VIRTUALLY.
GLAD TO BE WITH YOU TODAY.
THIS IS A DAY WITH INTERNATIONAL
AFFAIRS ARE ON EVERYONE'S MIND.
WE'VE SEEN THE SHOCKING IMAGES
OF WAR FOR THE FIRST TIME IN OUR
LIFETIMES AND IT'S SCARY AND
WORRISOME.
ALSO, AT NCI THIS WEEK WE'VE
BEEN MORNING THE LOSS OF Dr.
PAUL FARMER, A WELL-KNOWN
RESEARCHER AND LEADING PUBLIC
HEALTH ADVOCATE WHO RECENTLY
PASSED AWAY UNEXPECTEDLY AND HE
HAS I THINK CAME TO FAME FOR A
LOT OF HIS WORK ON GLOBAL
POVERTY AND IN THE HIV EAR AND
THE BURDEN OF GLOBAL CANCER
MEASURES TO REDUCE CANCER BURDEN
INTERNATIONALLY AND WAS
CERTAINLY A FRIEND OF THE NIH
AND THE NCI.
AND IT'S A BIG LOSS UNEXPECTED
DEATH OF A REAL ADVOCATE FOR LOW
AND MIDDLE INCOME HEALTH AND
CERTAINLY SOMEONE WHO GOALS WE
SHARE.
I KNOW THERE FARMER WOUL Dr. FARMER WOULD HAVE
BEEN INTERESTED IN THE NE WORK OF
THE NCI AND END CANCER.
WE'RE NOT TALKING ABOUT IT
TODAY, IS FREDERICK NATIONAL
LAB.
WE USE THE CAPABILITIES FOR
INTERNATIONAL STUDIES AS WELL AS
NIAID, AND IT'S IMPORTANT TO
SUPPORT OUR WORK IN OTHER
COUNTRIES.
SO AN ASPECT NOT LOST US ON
TODAY.
IT'S GOOD WORK AND WE NEED THE
ADVICE OF THE FIN AND I LIKE OUR
MEMBERS Dr. EARLY ROBERT SONSSON.
THEN DOWD CHAIR AND PROFESSOR OF
VICE-CHAIR OF THIS DEPARTMENT OF
PENNSYLVANIA SCHOOL OF MEDICINE
IN ADDITION HE IS A PROFESSOR
AND DEPARTMENT OF MICROBIOLOGY
AND HE IS A DIRECTOR OF THE
TUMOR TRAINING PROGRAMME THAT
ALREADY CAME IN HANDY AND HE
CORRECTED OUR MINUTES AND IS THE
ASSOCIATED DIRECTOR FOR GLOBAL
CANCER RESEARCH SO WELCOME TO
FNLAC, Dr. ROBERTSON.
TODAY, I THOUGHT I WOULD TALK
ABOUT THE PAST YEAR AND OUR WORK
WITH THE NATIONAL CANCER ACT
CELEBRATION FOR THE 50
ANNIVERSARY OF.
THE FISCAL YEAR '22 WHICH IS
UNCERTAIN.
ALTHOUGH SHOWING A LITTLE BIT OF
CHARITY.
THE PRESIDENT'S RECENT
ANNOUNCEMENT AROUND THE SUPER
CHARGED CANCER MOON SHOT AND
SOME OTHER EXCITING DEVELOPMENTS
IN CANCER RESEARCH, WITH A
FLAVOUR OF THINGS WORK DONE FOR
FREDERICK NATIONAL LAB.
I'LL TROY TO BE BRIEF SO WE HAVE
TIME FOR DISCUSSION.
NEXT SLIDE.
SO SINCE WE LAST MET, WE HAVE
ACTUALLY CELEBRATED THE ACTUAL
ANNIVERSARY OF THE SIGNING OF
THE NATIONAL CANCER ACT THAT WAS
DECEMBER 23rd OF 2022 AND WE
WERE REALLY GRATIFIED TO SEE A
REAL TSUNAMI OF INTEREST ACROSS
THE CANCER RESEARCH COMMUNITY
AROUND THE ANNIVERSARY AND
REALLY GOOD-BYE-IN FROM EVERYONE
INTERESTED IN CANCER RESEARCH
AND CANCER CARE AND A LOT TO
TALK ABOUT.
AS YOU CAN SEE, THERE WAS MEDIA
COVERAGE.
WE REPLACED TO SEE THE CANCER
CENTRES AND THE NATIONAL
SOCIETIES AND ORGANIZATIONS IN
THE CANCER RESEARCH GET INVOLVED
AND IT REALLY HELPED CREATE A
CONVERSATION ABOUT THE PROGRESS
IN CANCER RESEARCH THAT WE'VE
BEEN MADE TO DATE AND ALSO WHERE
WE HAVE TO GO AND WE HAVE
600,000 AMERICANS DYING FROM
CANCER AND THERE'S A LOT OF WORK
AHEAD OF US AND THE NCA50
ANNIVERSARY CAME AT A GOOD TIME
TO TAKE STOCK OF THAT PROGRESS
AND PIVOT AND PLAN IN THE FUTURE
WHICH IS VERY MUCH TOP OF MIND
GIVEN ENDING CANCER, AS WE KNOW
IT, IS A TOP PRIORITY FOR THE
JOE BIDEN ADMINISTRATION.
WE DO NOT HAVE A BUDGET FOR
FISCAL YAR '22.
WE'RE IN A CONTINUING
RESOLUTION.
IT'S EXTENDED UNTIL MID-MARCH.
SHOWN IS A SLIDE I SHOW THIS
GROUP OF OUR APPROPRIATION BY
YEAR FOR THE LAST FEW YEARS AND
YOU CAN SEE THE N.
>> Catherine: HATHEY HAVE BEENON A GOOD TR AJECTORY.
AND TO THE FAR-RIGHT IN THE
LIGHT BLUE, THE PRESIDENT'S
BUDGET FOR FY '22 AS WELL AS THE
HOUSE MARK FOR Y F-2 '2 AND
WE'RE WAITING ON THE ENACTED
BUDGET FOR FY '22.
YOU CAN SEE THE ORANGE BARS
THERE IN 2017 AND INCREASING
SIZE AND DECREASE IN SIZE THAT'S
THE 21st SEPTEMBER RECURES
ACTOR THE ORIGINAL CANCER MOON
SHOT AND THAT FUNDING IS SET TO
SUNSET IN 2023 AND SO IT'S A
GOOD TIME TO BE TALKING ABOUT
WHAT COMES NEXT IN TERMS OF MOON
SHOT AND IN THE GROW GREEN BAR, THE
$50 MILLION A YEAR FOR THE
CHILDHOOD CANCER DATA INITIATIVE
AND IT'S A INITIATIVE OF
$500 MILLION FOR CHILDHOOD
CANCER DATA.
AND IN 2021.
>> AND WE HOPE THE BUDGET WILL
BE SOON.
THE CR WAS EXTENDED UNTIL
MARCH 11th.
BUT WE DO HEAR THAT THE VARIOUS
APPROPRIATIONS COMMITTEES ARE
STARTING TO WORK TOGETHER AND
PLAN FOR THE FUTURE AND
HOPEFULLY A BUDGET WILL BE
FOURTH COMING.
UNTIL WE HAVE A BUDGET.
WE'VE HAD TO ADOPT A
CONSERVATIVE POSTURE WITH REGARD
TO SPENDING AT THE NCI INCLUDING
SPENDING IN THE EXTRAMURAL
RESEARCH POOLS.
SHOWN HERE ARE OUR INTERIM PAY
LINES AND FUNDING PLANS FOR
EXTRAMURAL GRANTS BURNING THIS
PERIOD.
I WANT TO STRESS, THESE ARE
INTERIM PAY LINES.
IF YOU ARE INTERESTED IN THIS
TOPIC, MORE IS AVAILABLE ON THE
BLOG SHOWN HERE.
WHEN WE HAVE A BUDGET FOR '22,
AS I EXPECT WE WILL, WE
HOPEFULLY WILL BE ABLE TO CHANGE
THESE PAY LINES UP IN OTHER
WORDS TO INCREASE OUR ACTUAL PAY
LINES FOR ESTABLISH
INVESTIGATORS FOR EARLY STAGE
INVESTIGATORS FOR R21s AND
ALSO TO SUBSTANTIALLY REDUCE OR
ELIMINATE THIS CUT TO NON
COMPETING GRANTS WHICH WE'RE
BEING FUNDED AT 90th PER
90th PERCENTILE.
IT'S CHALLENGEING AND WE'RE NOT
HAPPY ABOUT IT EITHER BUT
HOPEFULLY WE WILL SEE RESOLUTION
SOON AND I DID SEE
REPRESENTATIVE COLE AT THE
MOONSHOT EVENT AND HE IS A LEAD
APPROPRIATOR FOR THE NCI AND HE
TOLD ME STAY TUNED, WE THOUGHT A
BUDGET WAS IN THE OFFING SOON
ALTHOUGH, UNTIL WE KNOW THAT FOR
SURE WE HAVE TO WORRY ABOUT THAT
POSSIBILITY OF A FULL YEAR
CONTINUING RESOLUTION SOMETHING
NO ONE WANTS TO HAVE HAPPEN AND
WE DON'T EXPECT IT TO HAPPEN BUT
THAT'S WHY WE HAVE TO ADOPT
THESE CONSERVATIVE PAY LINES
UNTIL WE ARE CERTAIN THAT WE
HAVE CLARITY FOR '22.
NEXT SLIDE, WE'RE HOPEFUL FOR
'22 AND WE KNOW THERE'S PARTISAN
SUPPORT FOR CANCER RESEARCH AND
THIS IS EVIDENCE IN MANY WAYS
AND WHAT I'VE HEARD FROM
LEGISLATURES AS I MET WITH
DIFFERENT MEMBERS OF CONGRESS
BUT HERE IS A VERY NICE
EDITORIAL HERE SHOWN ON THE LEFT
AND IT APPEARED IN SCIENTIFIC
AMERICAN FROM SENATORS COONS AND
MORAN TALKING ABOUT A NEED TO
REALLY BOOST THE NCI BUDGET AND
THE NUMBER WAS A BILLION DOLLAR
BOOST UNDER THE BUDGET TO REALLY
MAKE PROGRESS IN CANCER RESEARCH
AND SUPPORT EXTRAMURAL FUND
FORGERON GRANTS AND THAT IS A
MISSION THAT WE STRONGLY SUPPORT
AND ALSO ON THE RIGHT, BEV A
NICE PIECE WRITTEN AND WHO IS
ALSO NOW THE ACI PRESIDENT AND
ROBERT WIN WHO IS THEY CITED A
2020 REPORT BY ACR AND THEY USE
DATA AND PROJECTED THE COST OF
CANCER WILL BE OVER $245 MILLION
A YEAR BY 2030 AND SO THEY OFFER
THIS PERSPECTIVE THAT IN THE
BUSINESS WORLD A STEADY RETURN
ON INVESTMENT RESULTS IN GREATER
EXPENDITURES IN ANTICIPATION OF
GREATER GAINS AND THE SAME
SHOULD BE TRUE OF CANCER
RESEARCH ARGUING THE MODEST SIZE
INVESTMENT OF FEDERAL MONEY IN
CANCER RESEARCH IS A GOOD USE OF
FEDERAL FUNDS GIVEN THE SIZE OF
THE PROBLEM OF $245 BILLION A
YEAR.
TWO WEEKS AGO, IN THE EAST ROOM
OF THE WHITE HOUSE, PRESIDENT
JOE BIDEN ANNOUNCED HIS PLANS TO
SUPER CHARGE THE CANCER MOONSHOT
AND AS I SAID IN CANCER AS WE
KNOW IT AND IT WAS A BIG MOMENT
FOR US.
THE CANCER RESEARCH COMMUNITY
WAS GALVANIZED AND AWAITING HIS
ANNOUNCEMENT IN THIS AREA THIS
AS WELL AS SEVERAL MEMBERS OF
CONGRESS AND IT'S GREAT THE
PRESIDENT SAID IT WAS A TOP
FINANCIAL PRIORITY AND EXPRESSED
SUPPORT FOR THE CANCER MOON SHOT
AND IT'S IMPORTANT TO NOTE THE
EXCESS OF THE INITIAL CANCER
MOON SHOT LAUNCHED IN 2016 HAS
BEEN SO LED BY DINA SINGER HAS
BEEN A LARGE CONTRIBUTING FACTOR
TO THE NCI PROGRESS IN THE PAST
FIVE YEARS AND THE PRESIDENT
POINTED TO THIS AS AN ENABLING
BROADER AND MORE AMBITIOUS SET
OF GOALS FOR THE FUTURE OF
MOONSHOT ACTIVITIES.
THE PRESIDENT'S ANNOUNCEMENT WAS
STEP ONE IN THIS PROCESS AND HE
LAID OUT SOME IMPORTANT GOALS
AND TALKED ABOUT PRIORITY AND I
SEEN THE COMMITMENT OF THE BIDEN
THIS IS THIS AREA AND IT'S
BIGGER THAN ONE AGENCY OR
OFFICE.
THE PRESIDENT TALKED ABOUT ALL
OF GOVERNMENT APPROACH TO
ADDRESSING CANCER AND INCLUDES A
CANCER CABINET.
I'M HONOURED TO BE A PART OF
THAT BUT IT'S TO BRING TOGETHER
DEPARTMENTS AND AGENCIES ACROSS
GOVERNMENT TO ESTABLISH IN A
PROGRESS ON THE GOALS OF ENDING
CANCER AND THIS INCLUDES 19
AGENCY INCLUDING HHS AND THE NCI
AND DEPARTMENT OF ENERGY, DOD,
CDC, FDA AND VA AND MANY OTHER
ACRONYMS AND IT'S CLEAR THAT NCI
WILL BE RESPONSIBLE FOR THE
RESEARCH OF THE WORK BUT THE
ADMINISTRATION UNDERSTAND THIS
IS BIGGER THAN ANY ONE AGENCY OR
OFFICE AND IT'S NOT JUST ABOUT
DEVELOPING NEW TREATMENTS OR
BETTER PREVENTION IT'S ENSURING
ACCESS AND HOW CARE IS DELIVERED
ACROSS COMMUNITIES AND PROMOTING
HEALTH EQUITY SO I THINK WE WILL
SEE IDEAS COMING OUT OF THE
CANCER CABINET.
THEY ANNOUNCED GOALS OF THE
CANCER MOONSHOT.
ONE TO REDUCE CANCER MORTALITY
ON THE ORDER OF 50% IN 25 YEARS.
ANOTHER THING HE REALLY FOCUSED
ON AND IT'S AN AMBITIOUS BUT
DOABLE GOAL AND I THINK IT'S
GREAT TO HAVE A HARD METRIC LIKE
CANCER MORTALITY WE MEASURE
ANNUALLY AND WE CAN AGREE IF WE
MAKE THE PROGRESS WE EXPECT AND
HOPE.
ANOTHER THING THE PRESIDENT
CALLED OUT WAS A FOCUS ON CANCER
PREVENTION AND SCREENING, THE
TOPIC OF RETURN TO SCREENING.
THE PRESIDENT AND THE FIRST LADY
HAVE SPOKEN ABOUT THE CANCER
EVENTS MISS DURING THE PANDEMIC
AND HOW WE NEED TO MAKE UP AND
IN ORDER TO REDUCE THE LONG-TERM
EFFECTS OF CANCER OUTCOMES FROM
THE PANDEMIC AND THIS IS I THINK
BEEN AN AREA OF VERY FRUITFUL
INTERACTIONS BETWEEN THE NCI AND
THE FIRST LADY'S OFFICE IN
PARTICULAR.
NEXT SLIDE.
SO, YOU KNOW, AS WE TALKED ABOUT
IT'S BEEN FRIGHTENING TO WATCH
THESE DRAMATIC REDUCTIONS IN
CANCER CARE AND SURGERIES AND
SCREENING EVENTS LIKE
MAMMOGRAPHY AND SO, THE NCI
WOULD LIKE TO DO THIS OTHER THAN
JUST MODEL THE PROBLEM AND TALK
ABOUT IT AND YOU KNOW, WE HAVE
SOME ABILITY TO COMMUNICATE AND
FUND RESEARCH IN THESE AREAS BUT
WE HAVE NOTHING LIKE THE FIRST
LADY'S IMPRESSIVE MEDIA MEGA
PHONE AND SO IT'S REALLY BEEN
GREAT TO HAVE HER AS A PARTNER
TALKING ABOUT THE IMPORTANCE OF
MISSED CANCER SCREENING EVENTS
AND HOW WE NEED TO RETURN TO
SCREENING AND THE FIRST LADY HAS
BEEN WONDERFUL TO WORK W SHE'S
GONE OUT ACROSS THE COUNTRY AND
ON NATIONAL MEDIA TO TALK ABOUT
THIS PROBLEM.
HERE ARE PHOTOS OF HER AT THE
MASSEY CANCER CENTRE IN RICHMOND
AND CHARLESTON IN SOUTH
CAROLINA.
YESTERDAY WE WERE AT SAN ANTONIO
AND THE WEEK BEFORE IN TAMPA AT
THE CANCER CENTRE SO SHE'S BEEN
GREAT ABOUT GOING ON THESE
VISITS TO CANCER CENTRES AND
TALK ABOUT CANCER SCREENING AND
SHE'S ALSO BEEN ON THE MEDIA A
BIT.
SO I THINK THIS IS BEEN VERY
HELPFUL TO GET THIS MESSAGE OUT
INITIALLY AND CERTAINLY AN
EXAMPLE OF HOW WORKING WITH THE
WHITE HOUSE, THE NCI CAN ADVANCE
ITS IMPORTANT GOALS.
NEXT SLIDE.
>> ALSO, IMPORTANT NEWS FROM THE
WHITE HOUSE LAST WEDNESDAY,
PRESIDENT JOE BIDEN ANNOUNCED
TEMPORARY LEADERSHIP TO FILL THE
VACANCY OF OSTP UNTIL PERMANENT
LEADERSHIP IS NOMINATED.
Dr. ALONDRA NELSON WILL
PERFORM THE DUTIES AND SCIENCE
ADVISORY OF THE PRESIDENT AND
CO-CHAIR OF THE PRESIDENT'S
COUNCIL ADVISERS ON SCIENCE AND
TECHNOLOGY AND THESE ARE REAL
FRIENDS OF CANCER AND INTIMATELY
THROUGHOUT THE YEARS OF THE NIH
AND SO WE'RE REALLY GLAD TO HAVE
HIM AND Dr. NELSON AS WELL
WORKING ON AREAS LIKE THE CANCER
MOON SHOT AND FINDING A NEW NIH
DIRECTOR AND MANY OTHER THINGS
ON THE WHITE HOUSE'S SCIENCE
DOCKET AT PRESENT.
NEXT SLIDE.
IN LIGHT OF RECENT EVENTS THAT
HAPPENED IN OSTP, I'D LIKE TO
TAKE A MOMENT TO EMPHASIZE ONE
THING VERY CLEAR LOW THAT THE
NCI'S UNEQUIVOCALLY COMMITTED TO
INSURING CIVILITY KINDNESS AND
MUTUAL RESPECT.
THESE ARE CORE VALUES OF THE
NATIONAL CANCER INSTITUTE AND
THE NIH AND THIS IS HOW PEOPLE
DO THEIR BEST WORK.
NCI IS NOT A PLACE WHERE WE
TOLERATE BULLYING OR HARASSMENT.
NIH POLICY IS VERY CLEAR AND I'M
SHOWING HERE A QUOTE FROM GARY
TABAK ABOUT HARASSMENT OR
INAPPROPRIATE COMMENT WILL NOT
BE TOLERATE AT THE NIH AND
TIMELY ACTION WILL BE TAKEN
AGAINST ANY INDIVIDUAL THROUGH
THESE POLICIES AND AT NCI WE
HAVE A WORKPLACE CIVILITY AND
ANTI-HARASSMENT PROGRAMME
COORDINATED BY THE COMMITTEE
MADE UP OF SENIOR
REPRESENTATIVES WE HAVE CLEAR
POLICIES AND PROVIDED TOOL KITS,
TRAINING AND ANTI-HARASSMENT AND
ONBOARDING AND EMPLOYEE
PERFORMANCE EVALUATIONS AND
WE'VE ALSO CHANNELED ACCESSIBLE
ANYONE TO REPORT SAFELY AND
DISCRETELY AND WE TAKE THIS
COMMITMENT VERY SERIOUSLY.
LET ME SHIFT BACK TO THE
MOONSHOT.
WE WANT TO REMIND EVERYONE WE'RE
STILL EXCITED ABOUT THE ORIGINAL
MOON SHOT AS WE'RE CALLING IT.
IT'S A WORK IN PROGRESS AS I
SAID AND WE HAVE FUNDING THROUGH
2023 AND HOW WE WERE
TRANSITIONED FROM MOON SHOOT
FUNDING WHERE NEEDED TO OTHER
FORMS OF NCI SUPPORT AND
CERTAINLY A VERY IMPORTANT
ADMINISTRATIVE PLANNING ACTIVITY
YOU CAN SEE AT NCI.
WE'RE PROUD OF THE RESEARCH
THAT'S BEEN FROST RESIDENT BY FOSTERED ON THE
MOONSHOOT.
WE HAVE A REVIEW ON THIS TOPIC
THAT IS PUBLISHED FOR THOSE WHO
WANT FURTHER DETAILS AND THERE'S
TREMENDOUS AMOUNT ON THE WEBSITE
AND I THINK THIS IS REALLY
ACCELERATED PROGRESS IN THE
TRANSLATIONAL SPACE AS WAS THE
GOAL OF THE ORIGINAL MOONSHOT SO
NOW AS I SAID IT'S A GREAT TIME
TO TALK ABOUT SUPER CHARGING
THIS FIRST EFFORT.
SO, YOU KNOW, WE'VE BEEN
THINKING THROUGH WHAT IT MEANS
TO END CANCER AS WE KNOW IT.
IT'S WHAT THE PRESIDENT ASKED US
TO DO AND WE WANTED TO TALK
ABOUT WHAT IT MEANS.
I'VE ALLUDE TODAY ONE WAY TO
THINK ABOUT ENDING CANCER AS WE
KNOW IT AND THAT'S THE PRISM OF
MORTALITY.
YOU THINK ABOUT A DRAMATIC TO
AGE ADJUSTED CANCER MORTALITY
AND I THINK IT'S A GOOD METRIC
TO THINK ABOUT IT.
NO ONE IS TALKING ABOUT
ERADICATING ALL CANCER.
WE DON'T THINK IT'S LIKELY BY
LOGICALLY PLOWS ABLE AN PLAUSIBLE SOON BUT WE
CAN IMPROVE CANCER OUTCOMES FOR
AWFUL OUR PATIENTS.
WHILE MORTALITY IS A VALUABLE
WAY TO THINK ABOUT IT IT'S THE
ONLY WAY TO THINK OF THE BURDEN
OF CANCER ON AMERICAN SOCIETY TO
WORKING WITH THE WHITE HOUSE, WE
DEVELOPED THESE OTHER AREAS
AROUND WHERE WE'D LIKE TO SEE
CANCER PROGRESS AND HERE ARE A
FEW OF THOSE AREAS THAT ARE IN
VISIONS SHOWN HERE NOT EVERYONE
PROMISING AVENUE OF RESEARCH OR
IT PRESENTS A PICTURE OF THE
SCALE AND SCOPE OF THE WHITE
HOUSE VISION AND THE DIRECTIONS
UNDERSTAND TO BE IMPORTANT AND
PROMISING AND AND IT'S
COMPREHENSIVE AND DIAGNOSIS AND
TREATMENTS AND PREVENTION AND IT
TALKS ABOUT PROMOTING HEALTH
EQUITY AND IT TALKS ABOUT DATA
AGGREGATION SO WE CAN LEARN FROM
ALL PATIENTS AND BY WORKING IN
THESE AREAS WE CAN CHANGE THE
NATIONAL EXPERIENCE OF CANCER
AND THERE BY END CAN
SARS-CoV-2 WKANSAS SER ASWEKANSAS SERCAN S ER AS WEKNOW IT.
OVER THE LAST A 15 YEARS OR SO,
YOU SEE A DRAMATIC REDUCTION OF
CANCER MORTALITY ACROSS THE
NATION IN ALL GEOGRAPHIES AND
REFLECTS MANY THINGS AND
ENHANCED THERAPY IN CANCER AND
MELANOMA AND THE GOAL IS TO
CONTINUE THIS PROGRESS AND TO
ACCELERATE IT.
ALSO THE PROBLEM WITH CANCER
MORTALITY IS MORE COMPLICATED
THAN I ENVISIONED THERE'S A
STRONG EFFECT THAT GEOGRAPHY.
GEOGRAPHY IS A PROXY FOR THINGS
LIKE RACE AND POVERTY AND ACCESS
TO CARE AND SO WE BELIEVE IT
REFLECTS THIS WITH REGARD TO
MORTALITY OUTCOMES AND COMPLEX
INTERACTION OF MANY OF THESE
SUCH FEATURES AND TO UNDERSTAND
THE ROOT CAUSES OF THE CANCER
DISPARITY SO WE CAN MAKE
PROGRESS FOR AWFUL OUR PATIENTS
AND I WANT TO POINT OUT THIS
NICE DISPLAY OF THE DATA IS
COURTESY OF THE DIVISION OF
CANCER CONTROL POPULATION
SCIENTIST.
AS MENTIONED THE WHITE HOUSE HAS
SET A BOLD MORTALITY GOAL TO
REDUCE CANCER BY 50% THE NEXT 25
YEARS AND THE REDUCTION OF AGE
DEATH AND MORTALITY FROM 146
DEATHS PER 100,000 TO 73 DEATHS
PER 100,000 THAT WOULD MAKE
CANCER A MUCH LOWER CAUSE OF
MORTALITY IN THE UNITED STATES
AND I THINK REALLY IT WOULD
CHANGE THE NATIONAL EXPERIENCE
OF CANCER IN MANY WAYS AND
REQUIRES US TO DO CERTAIN
THINGS.
CERTAINLY THERE'S NO SINGLE WAY
TO GET THIS KIND OF PROCEED AND
SO WE REQUIRE FOCUS ON
PREVENTION SCREENING AND
THERAPIES AND AND REALLY
ADDRESSING CANCER DISPARITIES
AND IT'S SOMETHING WE DON'T TO
MAKE IT POSSIBLE AND THIS IS ONE
THAT IS DOABLE.
NEXT SLIDE.
JUST TO FURTHER MAKE THIS POINT
ONE LAST TIME I THINK ONE WAY
YOU CAN GET A SENSE FOR THESE
DRIVERS OF CANCER EXPERIENCE
WHEN YOU AND CERTAINLY ALL RACES
INDIVIDUALS OF ALL RACES HAVE
SEEN A DECLINE IN CANCER
MORALITY FROM 2000 TO 2020
THAT'S GOOD NEWS BUT YOU CAN SEE
EVEN IN 2020 THAN OTHER RACES IN
THE UNITED STATES.
I THINK THE AMERICAN INDIAN
ALASKA NATIVE YOU CAN SEE THE
AGGREGATE STATISTICS FOR THIS
GROUP IS NOT EYE-POPPINGLY
DIFFERENT BUT THERE'S
HETEROGENEITY WITH SOME
GEOGRAPHIC REGIONS HAVING MUCH
HIGHER AGE OF DEATH AND
MORTALITY THAN OTHERS REFLECTING
THE HETEROGENEITY OF THE
POPULATION AND IN MANY OTHER
WAYS, MANY OTHER SOCIAL FEATURES
AND GIVING A CLEAR SENSE WHY YOU
ARE GETTING A HANDLE ON THESE
PROBLEMS AND UNDERSTANDING
DISPARITIES IS COMPLICATED AND
REQUIRES REALLY THOUGHTFUL USE
OF DATA AND CONSIDERING MULTIPLE
DIFFERENT FACETS AND ASPECTS.
ONE FOCUS OF THE PRESIDENT'S NEW
GOALS AS MENTIONED RELATED TO
THE CANCER IMPROVEMENT AND THE
NEW MOONSHOT IS PREVENTION AND
SCREENING AND EARLY DETECTION.
THESE ARE IMPORTANT TOOLS FOR
CONTROLLING CANCER AT THE
POPULATION HEALTH LEVEL AND
TACKLING EQUITIES AND CLOSING
GAPS AND SCREENING IN PARTICULAR
SO IT'S VERY TIMELY THAT IN THE
PRESIDENT'S CANCER PANEL,
RECENTLY RELEASED A REPORT ON
CANCER SCREENING IDENTIFYING KEY
BARRIERS AND PROVIDING
RECOMMENDATIONS TO INCREASE
EQUITABLE ACCESS SO HERE SAY
PHOTOGRAPH OF JOHN WILLIAMS AND
EDITH AND NED AT THE RECENT
CANCER EVENT AT THE WHITE HOUSE
SO WE THANK THE CANCER PANEL
ALONG WITH BO BOBBEN GRIM WHICH
CITED BARRIERS AND LACK OF
PROVIDER RECOMMENDATIONS,
GUIDELINES, FEARS OR CONCERNS
ABOUT MEDICAL PROCEDURES,
DIFFICULTY NAVIGATING THE
HEALTH-CARE SYSTEM TO ACCESS TO
SCREENING AND IT MAKES A CLEAR
RECOMMENDATION INCLUDING A
COMMUNITY ORIENTED OUTREACH TO
TRY AND ADDRESS MANY OF THESE
BARRIERS.
AND AS MENTIONED VERY MUCH A
PART OF THIS IS THE EFFECT OF
THE PANDEMIC ON CANCER CARE,
CANCER DIAGNOSIS AND CANCER
TREATMENT AND HERE DATA IS
SHOWING THE PLUMMET IN TERMS OF
SCREENING IN THE PANDEMIC AND
HAVE NOT FULLY RECOVERED.
YOU CAN SEE THIS IS DATA FOR
COLON CANCER SCREENING IF I
REMEMBER CORRECTLY AND 95% DROP
EARLY IN THE PANDEMIC AND NOT AS
I SAID A FULL RECOVERY AND WE
BELIEVE ON THE ORDER OF
10 MILLION SCREENING EVENTS IN
MISSED DURING THE PANDEMIC FOR
CANCER, AND NOW WE NEED TO TROY
AND MAKE UP THOSE DEFICITS TO
THE EXTENT POSSIBLE.
THE PRESIDENT CALLED FOR IN
SURING THAT EVERYONE IN THE U.S.
HAS EQUITABLY BENEFITS FROM
SCREENING THROUGH AT HOME
SCREENING AND ESPECIALLY FOR
COLON CANCER AND HPV THROUGH
MOBILE SCREENING AND COMMUNITIES
WITHOUT ACCESS TO A CLINIC
THROUGH THE USE OF COMMUNITY
HEALTH NETWORKS, AND MANY OTHER
WAYS TO REDUCE BARRIERS AND
AGAIN, CALLED ON THIS ALL OF
GOVERNMENT APPROACH TO TROY AND
ADDRESS THIS PROBLEM AND SO
CERTAINLY THE NCI WILL DO ITS
PART THROUGH ITS PROGRAMMES
INCLUDING THE CANCER CENTRES AND
OUR OTHER NETWORKS TO MAKE SURE
THAT CANCER SCREENING IS A
NATIONAL PRIORITY AND NCI WILL
COLLECT AND QUALITATIVE AND
QUANTITIVE DATA TO UNDERSTAND
THESE NEEDS AND WORK IN
PARTNERSHIP WITH OTHER AGENCIES
LIKE CMS, AND CDC AND HRSA ON
THIS TOPIC.
ONE AREA THE PRESIDENT MENTIONED
SPECIFICALLY IS THE EMERGING NEW
TECHNOLOGIES FOR MULTI-CANCER
DETECTION TESTS OR BLOOD TEST
THAT'S CAN DETECT MANY CANCER
SIMULTANEOUSLY AND OTHERWISE
HEALTHY INDIVIDUALS AND THE IDEA
IS YOU COME IN AND A PATIENT
AFTER A CERTAIN AGE, AGE 50
LET'S SAY WOULD COME IN AN ANNUALLY
AND SIMULTANEOUSLY SCREENING
WITH A HIGH SPECIFICITY, HIGH
SENSITIVITY ASSAY FOR MULTIPLE
CANCERS THAT WOULD BE REQUIRED
FURTHER STUDY, FOR EXAMPLE,
MULTIPLE PET SCANS OR SOMETHING
SHOULD THEY HAVE A APPEARANCE OF
A POSITIVE TEST.
WE THINK THESE TECHNOLOGIES AND
THERE ARE MANY OF THEM, THERE
ARE MORE THAN 20 OF THESE TESTS
IN DEVELOPMENT AND WE THINK
THEY'RE EXCITING AND CERTAINLY
HAVE VERY NOVEL APPROACHES TO
CANCER DETECTION AND COULD
REALLY HAVE AN IMPORTANT IMPACT
ON CANCER DETECTION AT THE
POPULATION LEVEL IF APPLIED
ROBUSTLY BUT WE ALSO HAVE
CONCERNS ABOUT THE ISSUES OF
OVER DIAGNOSIS AND OVER
TREATMENT WHICH ARE PROBLEMS OF
ANY CANCER SCREENING ASSAY AND
THE NCI STRONGLY FEELS WE NEED
TO DO THE RIGHT CLINICAL TRIALS
TO REALLY UNDERSTAND THE BENEFIT
OF THESE TECHNOLOGIES WHEN
APPLIED TO THE POPULATION LEVEL
AND THIS IS SOMETHING WE'LL TALK
ABOUT A LOT MORE.
WE ACTUALLY HAVE AN TOPIC OPEN
SEEKING RESPONSES AND CLOSES ON
MARCH 1st.
IF YOU ARE COLLEAGUES HAVE
THOUGHTS ABOUT MULTI CANCER
EARLY DETECTION TESTERS THE USE
IN THE GENERAL POPULATION,
PLEASE LOOK TO THAT RFI.
NEXT SLIDE.
WE WILL NEED IMPROVED
THERAPEUTICS AND NATURAL
PRODUCTS IN THE PAST AND THEY
HAVE BEEN AN IMPORTANT SOURCE OF
ANTICANCER MOLECULES AND BARRIE
O'KEEFE GAVE A NICE PRESENTATION
AT THE NCAB A FEW WEEKS AGO AND
HE STATED FORAY PROVED DRUGS OF
ALL USES AND THEY MAKE UP ABOUT
30% ON AVERAGE OF THOSE AGENTS
OVER THE YEARS.
HIGH SCREENING HAS INCREASES
OVER THE LAST 20 YEARS BUT THEY
DO HAVE A GO AHEAD
REPRESENTATION OF THAT FOR
PRODUCTS IN THE LIBRARIES AND
BECAUSE THESE THINGS ARE
DIFFICULT TO WORK WITH AND
DIFFICULT TO GET IT SCALED AND
IDENTIFY THE ACT OF MOIETY AND
WHEN YOU HAVE A HIT.
SO THE NCI IS WORK TO GO ADDRESS
THESE CHALLENGES AND WE HAVE THE
WORLD'S LARGEST COLLECTION OF
NATURAL PRODUCTS.
WE INITIATED A PROGRAMME USING
MOONSHOT FUNDING AND IT'S A
JOINT PROGRAMME BETWEEN DCTT AND
DCR FOR A NATURAL PRODUCTS
DISCOVERY PROGRAMME TO OVERCOME
CHALLENGE THIS IS NATURAL
PRODUCT BASED RESEARCH AND THIS
WORK IS INTIMATELY USES
FACILITIES AT FREDERICK NATIONAL
LAB AND FREDERICK NATIONAL LAB
IS ONE OF THE FEW LABS THAT HAS
THE ABILITY TO FRACTION EIGHT
THESE EXTRACTS AND DISTRIBUTE
THEM AT SCALE AND WE THINK NOW
WE'RE TRYING TO INCREASE USE
AGES OF THIS.
WE MADE A SIGNIFICANT
INVESTMENTS IN THIS IMPORTANT
REAGENT SOURCE.
WE HAVE MORE THAN A MILLION SEMI
PURE AND FRACTIONS AND WE WOULD
LIKE TO SEE USAGE INCREASE.
WE'VE ALREADY HAD HUNDREDS OF
THOUSANDS OF FRACTIONS RO RELEASED
TO THE PUBLIC AND WE HAVE SHIP
SAMPLES TO SCREENING CENTRES
WORLDWIDE AND IT'S BEEN USED
WIDELY ACROSS THE NIH NOT JUST
THE NCI BUT WE THINK IT'S A
GREAT RESOURCE FOR ACADEMIC DRUG
DISCOVERY EFFORTS AND WE HOPE
GREATER USE WILL BE FOURTH
COMING.
AND FOR THOSE OF YOU WHO HAVE
INTEREST IN THIS TOPIC, BARRIE'S
PRESENTATION TO FEBRUARY 10th,
IS AVAILABLE AT CANCER.GOV ON
VIDEO CAST.
A TEAM OF SCIENTISTS AT
FREDERICK NATIONAL LAB THE NCI
AND DATA FARBER, AND
BRISTOL-MYERS SQUIBB AND PFIZER
HAS A GENETIC VARIANT WITH
CHECKPOINT INHIBIT ORS MIGHT
FAIL AND THESE FINDINGS WHICH
APPEAR IN LANCE ONCOLOGY POINT
TO A HLA SUB TIGHT FOUND IN
PROTOZOAN 6.
THE PRESENCE OF THE HLA STAR 03
IN DNA WAS ASSOCIATED WITH
INEFFECTIVE SHOWN HERE IN THIS
SURVIVAL CURVE AND THE
CONNECTION WITH THESE POOR
RESPONSES COULD MAKE IT A USEFUL
SCREENING MARKET AND IT MAY BE A
CAUSE AS ASSOCIATED WITH ANTIGEN
PRESENTATION AND IMMUNE RESPONSE
IN THAT REGARD AND THIS IS A
REALLY IMPORTANCE SCIENCE OF
UNDERSTANDING THE RESPONSE TO
CANCER AND IT WAS AN EXAMPLE OF
THE SORT OF GROUND BREAKING
SCIENTIFIC CAPABILITIES
AVAILABLE AT FREDERICK NATIONAL
LAB.
NEXT SLIDE.
SCIENTIST LED BY STEVEN STERN
HAVE CREATED A NOVEL IMAGING
AGENT THAT MIGHT DETECT
PANCREATIC CANCER SOME DAY AND
AN EARLY STAGE WHEN IT WOULD BE
TREATABLE AND IMPROVE THE
PROGNOSIS FOR THE PATIENTS AND
THE DEPARTMENT OF MEDICINE AND
COLLABORATORS DEVELOPED A
NANOPARTICLE THAT ATTACHING TO A
EARLY STAGE.
THE SCIENTIST TESTED THE
NANOPARTICLE IN MICE TO DEVELOP
PANCREATIC CANCER AS WELL AS
CONTROL ANIMALS AND THESE
RESULTS WERE PUBLISHED IN THE
JOURNAL OF BIO MOLECULES AND
IT'S SO BUILD ON THIS WORK TO
DEVELOP A AGENT FOR USE HUMANS
AND TO CARRY THERAPEUTICS, AN
EXCITING POSSIBILITY AS WELL.
OUR NEXT SLIDE.
I WANTED TO MENTION A LITTLE BIT
OF WORK FROM THE RAS INITIATIVE
AND DOUG WILL TALK ABOUT THE
DEPARTMENT OF ENERGY
COLLABORATION AND THIS WORK ON
MULTI-SCALE MODELING TO MODEL
RAS BIOLOGY BEHAVIOR.
THIS GROUP IS FAMILIAR, RAS IS
IN CANCERS AND SO UNDERSTANDING
HOW IT ACTS AT THE CELL MEMBRANE
TO CELL SIGNALING IS A CRITICAL
Q WE'RE SEEING NOVEL
THERAPEUTICS IN THE CLINIC AND
FDA APPROVAL OF A RECENT AGENT
AND WE THINK THERE'S AN
OPPORTUNITY FOR MANY MORE
DISCOVERIES IN THIS THERAPEUTIC
CLASS AND THIS MODELING IS
ABSOLUTELY VITAL AND REVEALS THE
IMPORTANCE OF KRAS, LIPID
INTERACTIONS FOR DYNAMICS OF RA
S AND LOCAL DOMAINS OF KRAS IN
THESE CLUSTERS AND IT WAS PUB
LRT IN PNAS AND IT USED A MULTI
SCALE MODEL WHICH SIMULATES THE
BEHAVIOUR OF RAS, PROTEINS ON
REALISTIC CELL MEMBRANES AT
MULTIPLE SCALES SO THE LARGE
PROTEIN, THE LIPID SCALE AND THE
COMPLEX SCALE AND THE IT MUST
ACCOUNT FOR DIFFERENT POPULATION
AND WE WANT TO THINK ABOUT
CHILDHOOD CANCER.
NCI HAS BEEN COMMITTED TO
UNRAVELING CHILDHOOD CANCER
RECOGNIZING THE CHILDREN ARE NOT
JUST LITTLE KIDS, THEY HAVE
SPECIAL PROBLEMS AND NEED A
SPECIAL THOUGHT IN TERMS OF
THERAPEUTIC DEVELOPMENT AND
CANCER PATHOGENESIS SO OUR
EFFORTS AROUND THE CHILDHOOD
CANCER DATA INITIATIVE
DEMONSTRATED SOME OF THE UNIQUE
OPPORTUNITIES AND CHALLENGES
BEFORE US AND I THINK AS WE
TALKED ABOUT, DATA AGGREGATION
IS A NEED IN CHILDHOOD CANCER
WHERE ALL OF THE CANCERS ARE
RARE MALIGNANCY AND THE
OPPORTUNITY TO LEARN FROM EVERY
CHILD WITH CANCER IS THE GOAL OF
THE CCDI AND TO GET HELP ON
CHILDHOOD CANCER AND TO ADVISE
THE NCI AND ABOUT A NUMBER OF
CHILDHOOD CANCER, WE RECENTLY
ANNOUNCED THAT Dr. WEIDEMANN
WOULD BE THE SPECIAL ADVISER ON
THIS TOPIC.
SHE JOINED THE LEADERS AND WILL
ASSUME A LEADERSHIP ROLE.
SHE'S A WELL-KNOWN
INTERNATIONALLY FAMOUS
PRACTISING PEDIATRIC ONCOLOGY
WHO HAS COLLABORATED WITH MANY
EXTRAMURAL INSTITUTES AND THE
NCI CHILDHOOD CANCER PORTFOLIO
AND SHE RUNS THE PEDIATRIC
ONCOLOGY BRANCH AND IS
WELL-KNOWN FOR HER WORK IN RAS
ON AGENT' AND HER WORK LEADING
TO THE FDA APPROVAL.
WE'RE REALLY GLAD TO HAVE HER
USE AS ADVIS ADVICE AND HELP AND LOOK
FORWARD TO HER INPUT ON
CHILDHOOD CANCER SO WELCOME.
>> NEXT SLIDE.
I'LL CLOSE WITH THE REFLECTION
ON A RECENT EVENT AS I SAID I'VE
BEEN SO IMPRESSED WITH THE FIRST
LADY'S GRASP OF CANCER RESEARCH
AND HER SINCERITY AND GRACE FOR
WORK ON THIS ISSUE.
AT THE PODIUM, TWO WEEKS AGO,
SHE ECHOED WHAT I BELIEVE AND
THAT'S THAT WE'RE IN THIS GOLDEN
AGE OF CANCER RESEARCH.
I THINK THE LAST COUPLE OF YEARS
BEFORE THIS YEAR AND THE DECADE
TO COME WILL REALLY REMEMBER AS
A PERIOD OF VERY AND I THINK
THIS SPEAKS VOLUMES THAT SHE AND
THE PRESIDENT ARE FIRED UP TO
MAKE PROGRESS AGAINST CANCER BUT
THEY BELIEVE THE TIME IS NOW.
I FIND THIS SO INVIGORATING AND
EVERYONE THE PRESIDENT AT THE
WHITE HOUSE EVENTS FELT REALLY
ENERGIZED AND GALVANIZED BY THE
INTENSE FOCUS OF THE WHITE HOUSE
ON THIS TOPIC NOW AND THIS WILL
BE GOOD FOR CANCER RESEARCH AND
THIS IS GOOD FOR OUR PATIENTS
AND CERTAINLY FREDERICK NATIONAL
LAB HAS IMPORTANT REL TO PLAY IN
THESE EFFORTS.
SO WITH THAT I'LL CLOSE AND NEXT
SLIDE.
AND I WAS MOVED WITH THE MOON
SHOT PRESENTATION AND THE FIRST
LADY IT'S GREAT TO HAVE SUCH
RELATIONSHIP.
DOES ANYONE HAVE QUESTIONS?
>> THIS IS EARL ROBERTSON.
IN THE MAP OF THE ETHNICITY AND
RACE, OVER THE IT LOOKS LIKE
MONTANA AND DAKOTA AND MINNESOTA
AND NON HISPANIC BLACKS.
IS THERE ANY IDEA WHY THIS IS
AND ANY THOUGHTS AS TO WHAT IS
HAPPENING HERE OVER THE LAST
FOUR OR FIVE YEARS?
>> I'VE NOTICED SOME OF THOSE
THINGS ABOUT THOSE MAPS AS WELL.
IF YOU FOCUS ON SPECIFIC
POPULATIONS YOU SEE TRENDS THAT
ARE NOT INTUITIVE.
WE HAVE NOT DELVED IN YET
ALTHOUGH THIS IS IS AS I SAID,
SOMETHING WE BELIEVE REQUIRES
THINKING ABOUT THE GEOGRAPHY
WITH OTHER FEATURES WHETHER IT'S
A PROXY FOR ACCESS AND OR
FEATURE IN THOSE REGIONS SO THAT
I THINK IS A REALLY FRUITFUL
LINE OF RESEARCH THAT'S THE KIND
OF THING THE NCI FUNDS WITH
REGARD TO CANCER HEAL DISPARAGE
RESEARCH.
SOME OF THE SAME FINDINGS ARE
EVIDENCE IN THE AMERICAN INDIAN
ALASKA NATIVE POPULATION AND
KANSAS FOR EXAMPLE AND STILL
VERY HIGH AGE LESS MORTALITY
WHEN OTHER PARTS OF THE COUNTRY
HAVE SEEN A MUCH MORE PROGRESS
SO WHY THAT IS AND THE
POSSIBILITIES OF STATISTICAL
ARTIFACTS BECAUSE WE HAVE 50
COUNTRIES AND ARE DOING MULTIPLE
COMPARISONS BUT WHETHER THEY'RE
VALID FINDINGS OR REFLECTS
SOMETHING ELSE WE SHOULD KNOW
ABOUT IS ON GOING QUESTIONS FOR
FUTURE RESEARCH.
>> I THINK IN THE INTEREST OF
TIME, WE'LL GO ON.
THANK YOU, VERY MUCH, Dr.
SHARPLESS FOR YOUR SHORT.
WORE GOING TO GET AN UPDATE ON
THE NCI COLLABORATION Dr.
LOWY.
>> THANK YOU, VERY MUCH.
GOOD AFTERNOON FOR MANY OF YOU
AND GOOD MORNING FOR SOME.
I'M GOING TO DISCUSS WHAT HAS
HAPPENED IN THE LAST COUPLE OF
YEARS WITH THE NCI/DOE
COLLABORATION AND I WANT TO
THANK EMILY GREENSPAN, THE NCI
STAFF MEMBER, WHO COORDINATES
THIS COLLABORATION FOR US AND
INTERACTS EXTENSIVELY WITH THE
COLLEAGUES AT DOE.
I'VE ORGANIZED THE PRESENTATION
INTO THREE PARTS.
FIRST TO TALK ABOUT THE
COLLABORATION IN THE FIRST FOUR
YEARS THROUGH LAST YEAR.
SECOND, TO PUT SOME REAL
EMPHASIS ON THE EVALUATION TASK
FORCE THAT WAS PRESENTED TO THE
FNLAC AT THE END OF 2020.
WHAT THE RECOMMENDATIONS WERE,
AND HOW WE ARE IMPLEMENTING THEM
AND THEN TO DISCUSS SOME
HIGHLIGHTS OF THE CURRENT
PROJECT.
SO THE NEXT SLIDE, WILL
BASICALLY TELL YOU THAT
INITIALLY, THERE WERE THREE
PILOT PROJECTS.
THE PROGRAMME IS FINANCED ON THE
NCI SIDE BY THE CANCER MOONSHOT.
PILOT ONE WAS PREDICTIVE
MODELING FOR PRE CLINICAL
SCREENING AND PILOT 2 WAS RAS
BIOLOGY ON MEMBRANES AND Dr.
SHARP LESS TOLLESS TOLD YOU ABOUT THE
PUBLICATION AND PILOT 3,
POPULATION INFORMATION
INCOMPETENT INAUGURATION
INTEGRATION AND MODELING FOCUSES
ON THE SER PRO GRAM.
IT TELLS YOU ABOUT THE TASK
FORCE EVALUATION AND THERE WAS A
PRESENTATION ABOUT THE TASK
FORCE EVALUATION.
THE FIRST BULLET TELLS YOU THAT
THE COLLABORATION IS UNIQUELY
SUITED TO ADDRESS CERTAIN
CRITICAL CHALLENGE THIS IS
CANCER RESEARCH AND IT SHOULD BE
CONTINUED.
HOWEVER, THE CURRENT PILOTS WERE
REALLY MUCH LARGER THAN WHAT
WOULD CONSIDER A PILOT PROJECT
AND THEY SHOULD BE CONSIDERED
FULL SCALE PROJECTS AND SHOULD
BE VEI EVALUATED AS SUCH AND THERE
WERE TWO MAJOR SETS OF
RECOMMENDATIONS.
ONE FUTURE PROJECTS SHOULD BE
DEVELOPED AND RO REVIEWED BY A
STRUCTURED AND RIGOROUS APPROACH
TO ESTABLISH PROJECT-SPECIFIC
ADVISORY GROUPS.
TWO, TO INCREASE ENGAGEMENT WITH
THE NCI EXTRAMURAL COMMUNITY AND
THEN FOR THE SPECIFIC PROJECTS,
PILOT ONE WAS RECOMMENDED IT BE
CONCLUDED BECAUSE OF
INSUFFICIENT AVAILABLE AND
PERTINENT DATA AND OTHER
REASONS.
WHEREAS PILOTS 2 AND 3 SHOULD BE
CONTINUED.
SO THE NEXT SLIDE TELLS YOU WHAT
WE HAVE BEEN DOING MAINLY OVER
THE LAST YEAR IN RESPONSE TO THE
EVALUATION REPORT.
FIRST, THE QUESTION WAS, DID WE
GROAGREE WITH THE REPORT THAT THE
COLLABORATION SHOULD BE
CONTINUED AND THE ANSWER IS YES
AND LAST YEAR, WE SIGNED A NEW
FIVE-YEAR MEMORANDUM OF
UNDERSTANDING WITH THE DOE.
SECOND, FOR THE NEW FIVE-YEAR
COLLABORATION, THE OVERSIGHT
WILL BE DOE AND UNDER FNLAC
THEIR ADVANCE SCIENTIFIC AND I
HAVE A SLIDE THAT WILL SHOW YOU
ABOUT AND HOW THIS WILL BE FROM
THE TASK FORCE AND INCREASE
MURAL ENGAGEMENT AND REVIEW OF
PROJECTS AND INCREASE WORKSHOPS
AND HACKATHONS AND A DRASTIC
REVISION OF PILOT ONE.
NEXT SLIDE.
>> THIS SLIDE HAS MORE DETAILS
THAN I CAN GO OVER RIGHT NOW.
REALLY, IT'S A MULTIPLE SET OF
OVERSIGHT OF THE COLLABORATION.
FIRST THERE'S A SUBCOMMITTEE OF
THE D OOOH COMMITTEE AND IT'S
CHAIRED BY TONY HEY HE IS A
COMPUTER SIGN TIVE IN SEATTLE
BUT WITH EXTENSIVE EXPERIENCE IN
THE PRIVATE SECTOR AS WELL.
WE INTERACTED WITH HIM LAST
MONTH AND AS A RESULT OF SEEING
THE PEOPLE WHO WERE
PRELIMINARILY ON THE OVERSIGHT,
DINA SINGER, PROPOSED A COUPLE
OF ADDITIONS FOR MORE CANCER
BIOLOGY AND THAT'S IN THE
PROCESS OF HAPPENING.
THEY WILL BE DOE FROM THE
COLLABORATION SCIENTIFIC AND
TECHNICAL ADVISORY COMMITTEE AND
PROJECT 3 HAS THE COMMITTEE AND
PROJECT 2 AND 1 ARE IN PROGRESS
OF BEING DEVELOPED.
THERE WILL BE AN EXECUTIVE
COMMITTEE FOR THE COLLABORATION
OF NED, DINA AND I WILL BE
REPRESENTING NCI AND THERE WILL
BE COMPARABLE REPRESENTATION
FROM DOE.
NEXT SLIDE.
SO, I NOW WANT TO GO OVER
BRIEFLY, SOME HIGHLIGHTS OF THE
THREE INITIAL PILOTS AND THE
REVISION OF WHAT WAS ORIGINALLY
PILOT ONE.
THE NAMES HAVE BEEN CHANGED, I
THINK, BECAUSE THERE WAS AN
IRRESISTIBLE URGE TO HAVE AN
ACRONYM BECAUSE THE GOVERNMENT
DOESN'T HAVE ENOUGH OF THEM YET.
PILOT 3 IS NOW CALLED MOSAIC.
IT STANDS FOR MODELING OUTCOMES
USING SURVEILLANCE DATA AND
SCALABLE ARTIFICIAL INTELLIGENCE
FOR CANCER.
AND GEORGIA TERACI FROM THE OAK
LANGUAGE NATIONARIDGE NATIONAL LIBRARY.
THIS HIGHLIGHTS ONE OF THE
RECOMMENDATIONS AND TO MAKE IT
CLEAR THERE'S A GOOD DEAL OF
ACADEMIC INVOLVEMENT, EXTRAMURAL
INVOLVEMENT, WITH THIS PROJECT
AND IF YOU LOOK ON THE RIGHT
SIDE WHERE IT SAYS ACADEMIC
COLLABORATORS AND SUBJECT MODEL
EXPERTS, THOSE ARE LISTED THERE.
IT REHAVE SOME O REVIEWS SOME OF THE ADVAN CE
THAT'S HAVE BEEN MADE AND ONE IS
A NOTEWORTHY IS TO HAVE
EXTRACTION OF DATA SO THAT DATA
CAN BE DONE ESSENTIALLY
ELECTRONICALLY RATHER THAN
MANUALLY AND THIS HAS LED TO A
MORE THAN 15,000 TIMES FASTER
UPDATE FOR IN CORPORATING A
SUBSET OF PATHOLOGY REPORTS.
AND 17% OF ALL PATH REPORTS
CURRENTLY CAN BE CODED WITH MORE
THAN 97% ACCURATE SEE AND THE
NEXT CASE LEVEL IS TO GO UP
THROUGH ALMOST 25% COULD BE
CODED WITH THIS HIGH LEVEL OF
ACCURACY WHICH WILL SAVE A GREAT
NUMBER OF MANPOWER WHICH CAN
THEN AB PLIED TO OTHER
ACTIVITIES.
THEN, THIS HIGHLIGHTS ONE OF THE
CURRENT ACTIVITIES.
AND THAT IS SO FOR BREAST
CANCER, ESTROGEN RECEPTORS, AND
FOR COLON CANCER AND K RAS AND
MICRO STAT LIGH SATELLITE INSTABILITY.
ON THE RIGHT, THE ACCURACY AND
SENSITIVITY AND CURRENTLY PRETTY
GOOD BUT PROBLEM NEEDS TO BE
INCREASED FURTHER AND NEXT STEPS
ARE TRYING TO DO THAT PLUS IN
ADDITION, TO USE THESE ALGORITHM
ALGORITHMS BEYOND BEST AN BREAST AND
COLON CANCER.
THIS GOES INTO PILOT 2 BEING
CALLED ADMIRAL FOR ARTIFICIAL
INTELLIGENCE-DRIVEN MULTI-SCALE
INVESTIGATION OF RAS RAF ACT
ACTIVATION WITH INTEGRATION WITH
THE RAS INITIATIVE AND FRED
STRIPS FROM THE LAWRENCE LIVER
MORE NATIONAL LIBRARY BUT FRED
ACTUAL LO -- AND IT'S INTERACT WITH
RAH IN THE CONTEXT OF LIPIDS AS
NED MENTIONED, MULTI-SCALE
MACHINE LEARNED MODELING
INFRASTRUCTURE.
THIS HAS IDENTIFIED IN THE PNAS
PAPER USING A COM BENATION OF
EIGHT DIFFERENT LIPIDS THAT RAS
WHICH HAS BEEN A RELATIVELY NEW
RECOGNIZED PHENOMENON IS MORE
ATTRIBUTABLE TO THE LIPID
INTERACTIONS THAN IT IS WITH ANY
OTHER SINGLE INTERACTION.
AND IN THE MEAN CURRENT COAL,
AND AND BIOLOGY THROUGH THE RAS
INITIATIVE AND INTERACTIONS WITH
THE EXTRAMURAL COMMUNITY AND
DWIGHT AND FRED ARE REALLY
CHOMPING AT THE BIT TO TRY TO
HAVE AN IN-PERSON WORKSHOP TO
HAVE MORE ENGAGEMENT WITH THE VA
MURAL COMMUNITY BUT IT'S BEING
HELD BY DEBBIE MORRISON FROM NCI
BUT LOCATED IN FREDERICK IN THE
SAME AREA AS THE RAS INITIATIVE
WHO IS NOW, HER RESEARCH IS MORE
INTEGRATED WITH THE INITIATIVE.
I'M NOT GOING OVER THE NEXT
SLIDE IN DETAIL.
IT SHOWS YOU REALLY THERE ARE
SEVERAL STEPS BETWEEN HAVING RAS
AND RAF OF BEGINNING TO BE
TOGETHER BUT INITIALLY RAF IS AN
INACTIVE SET AND THEN THERE'S AN
OPENING OF THE AUTO INHIBITED
RAF PROTEIN WHEN 1433 PROTEINS
SHOWN ON THE LEFT DISENGAGE AND
THEN DELINEATE THE LARGE SCALE
DOMAIN REARRANGEMENT OF THE
RAS-RAF SHOWN IN 2 AND IN 3 TO
DESCRIBE THE RAF DOMAINS IN
ASSOCIATION WITH THE KRAS DIME
ORIZATION.
IT'S THE RECONFIGURATION OF WHAT
WAS ORIGINALLY PROJECT 1.
WHICH HAS REALLY NOW BEING
CALLED IMPROVED, INNOVATIVE,
METH ODDOLOGY AND NEW DATA FOR
MODEL EVALUATION AND WE THINK
THAT IT NOW HAS A LOT OF
POTENTIAL.
RICK WILL LEAD IT FROM THE DOE
SIDE AND RYAN WILD FROM FNL WILL
BE THERE AND THERE WILL ALSO BE
NCI OVERSIGHT INVOLVEMENT
PROBABLY WITH JEFF HILLDISIDE.
IT BUILDS ON WHAT WAS LEARNED IN
PILOT ONE BUT DESIGNED WITH NEW
ENGAGEMENT MODEL AND THE CANCER
RESEARCH COMMUNITY AND DOE LABS.
THERE ARE TWO RELATED GOALS
AIMED AT IMPROVING DEEP LEARNING
MODELS FOR PREDICTING DRUG
RESPONSES AND TUMORS.
DEVELOPING SEMI AUTOMATIC
PROTOCOLS FOR COMPARING DEEP
LEARNING MODEL FROM VARIOUS
INVESTIGATORS TO IDENTIFY MODEL
ATTRIBUTES THAT CONTRIBUTE AND
IMPROVING FUTURE MODELS AND YOU
WILL SEE HOW THERE'S COMPLETE
INTEGRATION PROPOSED FOR THE
EXTRAMURAL COMMUNITIES.
AND AIM 2, BASED ON
RECOMMENDATIONS FROM THE GROUP
INVOLVED WITH AIM 1 TO PRO
INVITE PROTOCOLS FOR DRUG
SCREENING EXPERIMENTS AND
GENERATE DATA AIMED AT MODEL
PERFORMANCE.
NEXT SLIDE.
SO THIS IS THE IMPACT FROM AND
GENERATING NEW TREATMENT
APPROACH AND YOU CAN TOOK AT THE
OTHER BULLET HOW THIS IS GOING
TO BE DONE.
NEXT SLIDE.
THIS SLIDE AND THE NEXT SLIDE
REALLY IDENTIFY TWO KEY
BOTTLENECKS FOR MAKING PROGRESS
AND HOW THE PROJECT PERHAPS TO
DEAL WITH THEM.
BOTTLENECK ONE, IS TO COMPARE
THE NEW MODELS TO PREVIOUS
MODELS AND HOW TO QUICKLY AND
FAIRLY COMPARE THEM AND OTHER
ASPECTS AND GO BEYOND SIMPLE
VALIDATION APPROACHES TO MORE
BIOLOGICALLY RELEVANT ASSESSMENT
WORK WITH THE COMMUNITY TO
DEVELOP MORE STANDARD APPROACHES
AND THE GOAL BEING AN AUTOMATED
FRAMEWORK TO MAKE MASSIVE CROSS
COMPARISONS FEASIBLE.
THE NEXT SLIDE, HOW TO ADDRESS
BOTTLENECK 2, WHICH IS WHAT DATA
NEEDS TO BE GENERATED TO IMPROVE
THE MODEL AND THEY WERE NOT
CREATED FOR THIS PURPOSE SO
TRYING TO ESSENTIALLY DO THAT
HOW DATA QUALITY EFFECTS MODEL
PERFORMANCE AND THE LEARNING
CURVE SCALING BEHAVIOR ACROSS
MODELS AND THE FEATURE TYPES AND
MODALITY OF TRAINING DATA AND
THE IMPACT OF DATA DIVERSITY AND
DRUG AND TUMOR SPACE WITH THE
GOAL OF THE NEW DATASETS
EXPLICITLY GENERATED TO IMPROVE
MODELS AND MAKE THEM WIDELY
AVAILABLE AND THE LAST TWO
SLIDES FOR THIS PART, IN MANY
WAYS ARE THE MOST IMPORTANT.
TO FIRST TO ENGAGE THE
COMMUNITY.
THE LABS WILL USE AN RFI/RFP
PROCESS ADMINISTERED BY THE
FNLAC TO SUPPORT TO PARTICIPATE
IN DOUGH SIGNIN DESIGNING AND IMPROVING TH E
FRAMEWORK.
THE LABS WILL BE INVOLVED AND
FOR AIM 2, THEY WILL BE AN
RFI/RFP WITH A QUALIFICATION
ROUND AND THIS PROCESS WILL BE
USED TO IDENTIFY COMMERCIAL
FIRMS OR OTHER THIRD PARTIES
THAT CAN BE CONTRACTED WITH TO
PRODUCE DATA SPECIFIED BY THE
CORE MODELING GROUP.
THE LAST SLIDE, IN THIS PART,
FOR IMPROVED SHOWN IN THE NEXT
SLIDE, IS THAT EVERYTHING SHOULD
BE OPEN.
THE FRAMEWORK, THE MODEL
ANALYSIS CYSTS AN AND ALL DATA IS OPEN
SOURCE AND AVAILABLE TO THE
WHOLE COMMUNITY.
WHOLE DEVELOPMENT HACKATHONS AND
ANNUAL MEETING THAT WILL BE
OPEN.
AND IMPROVE WILL WORK WITH
AGENCIES, SCIENTIFIC
ASSOCIATIONS AND JOURNALS TO
ADVOCATE FOR OPEN MODELS, OPEN
DATA AND OPEN SOURCE ENABLING
REPLICATIONS OF MODELING
RESULTS.
MY LAST SLIDE, THE NEXT SLIDE,
BEFORE I GET TO THE CONCLUSION,
JUST SAYS THAT THERE ARE SOME
OTHER AREAS BEING EXPLORED FOR
POSSIBLE FUTURE COLLABORATION
AND ONE OF THEM IS THE AREA OF
RADIATION ONCOLOGY WHICH IS AN
INTEREST BOTH OF DEO AND OO E&N CI E AND N CI.
LET ME SUMMARIZE WHERE WE ARE.
FIRST, NCI IS CONTINUING ITS
COLLABORATION WITH THE DOE.
THE RECOMMENDATIONS OF THE
EVALUATION TASK FORCE ARE BEING
IMPLEMENTED.
THIRD, IT'S ANTICIPATED THAT
INCREASED INCOMPETENTEINCREASED INNER ACTI ON AND
ADVISORY GROUPS WILL INCREASE
THE ACHIEVEMENTS, AND THE IMPACT
OF THE COLLABORATION.
THANK YOU, I LOOK FORWARD TO
YOUR QUESTIONS AND COMMENTS.
>> THANK YOU.
GREAT PRESENTATION Dr. LOWY.
ANY QUESTIONS?
LINCOLN.
>> YEAH, QUICK ONE.
I WAS DELIGHTED TO SEE THE
PROJECT TO EXTRACT BIOMARKERS
FROM PATHOLOGY REPORTS AND I WAS
WONDERING IF THERE WERE ANY
PARALLEL EFFORTS TO WORK WITH
THE SOCIETY'S CAP IN ASCP TO SET
BIOMARKER SECTION OF BIOMARKERS
ASIDE IN THE REPORT AND
STANDARDIZE THEM TO MAKE THE
MACHINE LEARNING MUCH EASIER?
>> THAT'S A GREAT QUESTION.
I DIDN'T HAVE TIME TO GO OVER
IT, BUT THERE ARE PLANS FOR
OUTREACH OF THE BEYOND THE
PROGRAM WHICH CAN INCLUDE WHAT
YOU ARE DISCUSSING AS WELL AS
OTHER POS POSSIBILITIES.
>> THANK YOU.
>> ANDREA, Dr. BUILD.
>> HI, THANK YOU.
NICE PRESENTATION.
I HAD TWO QUESTIONS.
ONE IS WITH THE IMPROVED PLANS.
WAS THERE PLANS TO ENCLOUD
PATIENT DATA BUILDING OFF OF
COURSE INVOT INVITO --
>> WHAT KIND OF PATIENT DATA?
>> SO, AS YOU KNOW, WITH
MODELING DATA AND IMPROVING
PREDICTIONS, IT'S IMPORTANT TO
HAVE A INVIVO DATA SET FOR
COMPARISON WITH THE INVITO
STUDIES.
SO I'M CURIOUS IF THE IMPROVED
PLANS INCLUDE --
>> OH, YES.
IT WILL BE PART AND PARCEL OF
THE PROJECT.
>> MY SECOND QUESTION WAS LINKED
TO THE EARLIER PART OF THE
PRESENTATION WHERE THE
COLLABORATION HAS ENORMOUS POWER
IN TAKING COMPLEX DATA AND
ANALYZES AND PROCESSES AND
LINKING THEM TOGETHER SO
RESEARCHERS CAN MORE EASILY USE
THE DATA.
SO, I'M INTERESTED IF YOU ARE
PLANNING TO PURSUE THIS FURTHER
IN THE CONTEXT OF OTHER WIDELY
USED DATABASE SUCH AS DB GAP AND
OTHER DATABASES THAT
INVESTIGATORS USE TO MAKE THEM
ALSO EASY TO USE AND MORE WIDELY
APPLICABLE TO OTHER STUDIES.
>> THIS IS A GREAT QUESTION.
COULD WE DISCUSS THIS OFF LINE?
EITHER LATER TODAY OR IN THE
COMING WEEKS?
BECAUSE, I REALLY WANT TO GET
YOUR IDEAS SO THAT WE CAN TRY TO
I AM NOT THEM.
>IMPLEMENT THEM.
>> ABSOLUTELY.
ANY TIME.
>> THANK YOU, ANYONE ELSE.
GREAT PRESENTATION, Dr. LOWY.
SO, NEXT ON THE AGENDA IT'S MY
PLEASURE TO INTRODUCE Dr.
JANET EARY SHE'S GOING TO TALK
TO US ABOUT THE CANCER IMAGING
ARCHIVE.
>> THANK YOU SO MUCH, GOOD
AFTERNOON, EVERYONE.
THIS IS A GREAT UNDER FOR US TO
TALK ABOUT THE ARCHIVE.
IT'S A VERY BUSY PLACE AND IT
GETS BUSIER AND HAS MORE
INTEREST ALL THE TIME.
SO, NEXT SLIDE, PLEASE.
HERE IS THE LANDING PAGE FOR THE
ARCHIVE.
IT'S VERY EXCITING LOOKING.
ALL THESE IMAGES COMING OUT OF A
SCANNER.
ONE OF THE THINGS THAT WE WANT
TO EMPHASIZE WHEN WE TALK ABOUT
THE ARCHIVE IS RIGHT THERE IN
THE LANDING PAGE IF YOU SEE THE
BOXES DOWN BELOW THE WELCOME
MESSAGES, THERE'S A BUTTON TO
SAY SUBMIT YOUR DATA OR ACCESS
THE DATA AND THAT'S WHAT THE
IMAGING ARCHIVE IS ALL ABOUT.
NEXT SLIDE.
I GUESS THIS ONE IS ANIMATED.
THERE WE GO.
IT'S FOR CANCER RESEARCH DATA.
ITS PRIMARY JOB AND THE REASON
IT WAS SET UP INITIALLY WAS TO
PROVIDE DEIDENTIFIED CURATED
IMAGE DATASETS FOR THE RESEARCH
COMMUNITY CANCER RESEARCH
COMMUNITY AND RESEARCH COMMUNITY
IN GENERAL.
AND THE DATASETS ARE IMAGES AND
THEY START OUT PRIMARILY
STANDARD CLINICAL IMAGES SUCH AS
CT AND MR PET SCANS.
AND THEY CONSIST OF IMAGES OF
PATIENT GROUPS WITH STANDARD
CANCERS AND MORE RECENTLY,
UNIQUE OR RARE TYPES AND OR
SPECIFIC CLINICAL APPLICATIONS.
AND THE ARCHIVE HAS EVOLVED, WE
HAVE PLACED MORE EMPHASIS ON
INVESTIGATORS SUBMITTING
ASSOCIATED METADATA FOR
INTEGRATED DATA ANALYSIS.
FOR HYPOTHESIS GENERATION,
GETTING A LOOK AT WHAT THIS TYPE
OF DATA LOOKS LIKE FOR
RESEARCHERS OUTSIDE THE CANCER
COMMUNITY, AND OF COURSE, FOR
THOSE PEOPLE WHO WERE DOING
OTHER EXPLORATIONS FOR THE GRANT
RESEARCH WORK.
MOST RECENTLY, WE'VE BEEN
EXPLORING INCORPORATING NEW DATA
TYPES FROM DIFFERENT TYPES OF
IMAGING DATA AND DEVELOPING NEW
DATA SHARING.
NEXT SLIDE.
THE TCIA SET UP A DATA RESEARCH
NEED.
IMAGES ARE RICH DATASETS.
THEY HAVE -- THEY'RE IN 3D SO
THEY HAVE A LOT OF SPACIAL
INFORMATION AND A LOT OF
TEMPORAL INFORMATION BECAUSE
THEY'RE TAKEN USUALLY OVER TIME
OF A PATIENT OR AN ANIMAL MODEL
AND THEY HAVE A LOT OF DATA,
STATISTICIANS LOVE IT SO IT'S
USEFUL REGARDLESS OF THE TYPE OR
THE QUESTION AND OF COURSE,
IMAGING IS NOT INVASIVE.
THE ARCHIVE IS FUNDED AND
GOVERNED BY US AND DCTD IN THE
CANCER IMAGING PROGRAM AND IT'S
MANAGED BY THE FNLCR BY JOHN
FRYMAN AND HE AND HIS TEAM
MANAGED SUB CONTRACTS THE
UNIVERSITY OF ARKANSAS WHERE THE
ARCHIVE IS ACTUALLY HOUSED.
WITH INPUT FROM EMERY UNIVERSITY
AND IROCK AND STONEY BROOKE AND
CLOSE FROM THOSE OF US IN THE
CANCER MACHINE PROGRAM.
THOSE ARE EVALUATED FOR THEIR
SCIENTIFIC RELEVANCE AND NUMBER
OF OTHER FACTORS WHICH I'LL
DESCRIBE LATER.
BY THE TCIA ADD VOICE ROW GROUP,
WHICH HAS MEMBERS OF THE CANCER
IMAGING PROGRAM AND THE
RADIATION ONCOLOGY, LIDOS GROUP
AND PATH OLE GOOD EVENING FROM
DCTD AND FROM THE CAMPUS, THE
CAMPUS CANCER PROGRAMS.
AND THE PROPOSALS COME PRIMARILY
FROM INVESTIGATORS AND THEIR
RESEARCH GRANTS BUT THEY CAN
ALSO COME AS QUESTIONS SETS FOR
CHALLENGE COMPETITIONS AND OTHER
REQUESTS FOR PUBLIC DATA SHARING
AND INCREASING LO LOW INCREASINGLY WHERE T HERE ARE
PUBLICATIONS REQUIREMENTS BY THE
JOURNAL.
NEXT SLIDE.
WE SUPPORT A NUMBER IN ADDITION
TO COLLECTING DATASETS FROM
INVESTIGATORS ACROSS THE
COMMUNITY, WE ALSO SUPPORT A
NUMBER OF NCI RESEARCH
INITIATIVES AND THOSE ARE LISTED
HERE AND I'LL GO INTO THOSE IN
MORE DETAIL BUT IT'S A WIDE
BREADTH AND SPAN WHERE IMAGING
IS PART OF THE DATA COLLECTION
WITH THESE OTHER TYPES OF
ACTIVITIES AND WHAT WE DO
PRIMARILY FOR THOSE IS CURATE
THE STANDARD OF CARE CLINICAL
IMAGE DATA AND MAKE SURE THAT
THEIR DEIDENTIFIED AND READY TO
BE USED FOR ANY TYPE OF
RESEARCH.
SO HERE IS THE REVIEW CRY TER
WHY FOR A DATA SET AS IT
COMES -- CRITERIA FOR A DATA SET
AS IT COMES IN.
THE COMMITTEE IS CHARGED WITH
EVALUATING AND HOW IMPORTANT IS
THIS DATA SET FOR P FOR FACILITATING
CENTER?
DOES IT ADDRESS A DATA GAP FOR
CURRENT RESEARCH OR A CLINICAL
NEED?
IS IT NOVEL COMPARED TO WHAT WE
ALREADY HAVE AND THE ARCHIVE.
IT'S AN UPDATED VERSION?
IS IT LARGE ENOUGH WITH ENOUGH
PATIENTS AND ENOUGH IMAGES TO
SUPPORT ANALYSIS OR HYPOTHESIS
DEVELOPMENT?
SOMETIMES WITH A PROBLEM WITH
RARE OR UNIQUE CANCERS OR UNIQUE
CLINICAL SITUATIONS WHERE THERE
MIGHT BE AN EXTREMELY IMPORTANT
DATA SET WHICH ONLY HAS CONSISTS
OF IMAGING AND MAYBE OVER SIX
MONTHS PER 20 PATIENTS OR SO SO
WE HAVE TO EVALUATE THOSE VERY
CAREFULLY.
DOES THE DATA SET CONTAIN AND
THIS MAY OR MAY NOT BE A PROBLEM
AND INVESTIGATORS WANT TO SEND
TO US RESULTS OF THEIR IMAGE
ANALYSIS AND ONE OF THE THINGS
THAT WE'RE VERY CONCERNED ABOUT
IS MAKING SURE IF THERE ARE
ANALYSIS DATASETS, BASED ON
ARCHIVE DATA OR THE
INVESTIGATORS OWN DATA, WHETHER
OR NOT IT'S A HYPOTHESIS OR
OTHER PATHO PHYSIOLOGICAL ASPECT
OF CANCER AND IN OTHER WORDS,
NOT JUST AN ARRAY OF NUMBERS.
SO WE ASK HOW ARE THE RESEARCH
COMMUNITY BENEFIT FROM THIS
DATA?
AND, WHAT WAS THE CRITERIA USED
TO DETERMINE THE METHODOLOGY OF
THESE ANALYSIS.
THEY GET COMPLICATED AS TIME
GOES ON AS WE RECEIVE DIFFERENT
REQUEST FOR DATA HOSTING AND THE
DEMANDS OF THE COMMUNITY HAVE
CHANGED.
SO, OBVIOUSLY YOU CAN SEE THAT
WE'VE CONTINUED TO EVOLVE OUR
CRITERIA AND REVIEW OF DATA
ANALYSIS THAT COME THROUGH AS
WELL TO BE HOSTED.
WE HAVE WORLDWIDE CONTRIBUTIONS
OF DATASETS FROM DIFFERENT
INSTITUTIONS AND ALL OVER THE
WORLD AND IT'S INTERESTING
BECAUSE THEY HAVE DIFFERENT DATA
AND POLICY SHARE ISSUES AROUND
THE WORLD AND OF COURSE
DIFFERENT IMAGE FORMATS AND
DIFFERENT CHALLENGES AND
DEIDENTIFICATION FOR HOSTING AND
CURATING.
NEXT SLIDE.
THE ACTUAL WORKING COMPONENTS OF
THE ARCHIVE IS AS YOU WOULD
EXPECT THE DATA COLLECTION
FUNCTION AND THEN THAT CONSISTS
OF SPECIALIZED DEIDENTIFICATION
AND ALGORITHMS AND PROCESSES AND
TOOLS TO SUPPORT DATA COLLECTION
AND BRINGING IMAGES IN FROM THE
SOURCE AND PUTTING THEM TOGETHER
IN A WAY THAT MAKES SENSE AND
THEY'RE DISCOVERABLE IN THE
ARCHIVE AND OF COURSE,
DEIDENTIFICATION.
THIS IS CARRIED OUT BY
SPECIALIZED TEAMS FOR DIFFERENT
IMAGE DATA TYPES AND OF COURSE
THEN WE HAVE IN A VERY ACTIVE
SUPPORT DESK FOR FOLKS TO CALL
IN AND FIGURE OUT HOW TO USE THE
ARCHIVE IF THEY'RE HAVING
PROBLEMS.
I KNOW IT'S ACCESSIBLE AND THERE
ARE OTHER TYPES OF TOOLS THAT
ARE AVAILABLE AND GRAPHIC USER
INTERFACE AND OTHER PROBLEMATIC
INTERFACES FOR PEOPLE TO USE WHO
ARE ALSO DOWNLOADING THE
DATASETS.
WHAT IS IT ABOUT IMAGES AND THE
DEIDENTIFICATION WE TALKED
ABOUT.
THE ARCHIVE IS PUBLIC AND THAT
MEANS ANYBODY CAN ACCESS IT AND
DOWNLOAD IMAGES OR HAVE A LOOK.
CLINICAL IMAGING DATA AND A LOT
OF ANIMAL MODEL RESEARCH DATA
HAS LOTS OF IDENTIFIERS BUT WE
HAVE PATIENT-RELATED PRIVATE
INFORMATION AND IT'S NOT JUST ON
THE RED BOX WITH THE PATIENT'S
NAME, DATE OF BIRTH, THE DATE OF
THE IMAGING STUDY AND THE
PATIENT NUMBER, THERE'S PERSONAL
INFORMATION THROUGHOUT THE
ENTIRE IMAGE DATA SET IN PIXELS
AND ALL OVER THE PLACE AND IN
PLACES YOU DON'T SEE THAT IS
ACTUALLY EMBEDDED IN THE IMAGE
AND THIS IS AND THAT'S A
CRITICAL ASPECT TESTIFY AND WHY
IT'S SO WIDELY USED AND
WELL-KNOWN.
AND THAT IMAGING DATA PHI IS
EVERYWHERE IN IT AND NEXT
SLIGHT.
A NUMBER OF IMAGING SETS AND
THEY HAVE MR AND CT IMAGES WITH
THOUSANDS OF IMAGES FOR TIME
POINT SO THERE'S 50 MILLION
IMAGES AND BEEF BEEN ACQUIRING
HYSTE PATHOLOGY IMAGES AND
ASSOCIATED SUPPORTING DATA.
THERE'S ALSO A COVID-19 DATA SET
AND I'LL TALK ABOUT THAT IN A
MINUTE.
SCIENTIFIC IMPACT.
LOTS OF USERS FROM AROUND THE
WORLD AND WHERE THE DATA
PUBLISHER AND REPOSITORY OF
RECORDS FOR A NUMBER OF JOURNALS
AND WE CONTINUE TO SEE AN
INCREASE IN PUBLICATIONS BASED
ON DATA THAT IS IN THE DATA SET.
NEXT SLIDE.
SO, WE THINK WE ARE LEADING THE
WAY FOR PUBLIC DATA SHARING.
SO THERE ARE A NUMBER OF ASPECTS
THAT ARE REALLY IMPORTANT FOR
THE RESEARCH COMMUNITY.
WE COLLECT DATA OR AUTHO AUTHOR AS
WELL. AND WE HAVE THE NATIONAL
LIBRARY OF MEDICINE TO EACH DATA
SET O SO IT COUNTS AS A
PUBLICATION FOR THAT
INVESTIGATORS AND AND THEY ALLOW
RESEARCH EX COMMERCIALIZATION
AND THAT HAS DIFFERENT
IMPLICATIONS DEPENDING UPON THE
COUNTRY OF ORIGIN FROM THE DATA
SET AND WE DO NOT INSIST ON A LOG
IN OR PARAMETERS AND IT'S REALLY
OPEN AND ACCESSIBLE.
WE ALSO, AS I MENTIONED EARLIER,
WE HAVE A NUMBER OF JOURNALS AS
PARTNERS SO WE'RE PERMITTED DATA
SHARING SPACE AND REPOSITORY FOR
DATA SHARING REQUIREMENTS AND BY
THE JOURNALS AND RECENTLY THE
NIH HAS RECOGNIZED THE TCIA IS
AN NIH HIGH VALUE DATA ASSET.
THERE ARE ONLY A HANDLE OF THESE
THAT HAVE BEEN IDENTIFIED AND
SO, ALL ASPECTS OF THE TCIA ARE
BEING EXAMINED FOR HOW IT
FUNCTIONS AND WHAT IT'S
GOVERNANCE IS AND WHAT THE KEY
ISSUES ARE IN ITS MANAGEMENT AND
SUSTAINABILITY.
SO, WE'RE PLEASED TO BE SERVING
AS AN EXAMPLE AND HAVING A LOT
OF INFORMATION INTO INPUT INTO
THE DISCUSSIONS.
I AM A MEMBER OF THE HIGH-VALUED
DATA A ASSET COMMUNITY SO IT'S
BEEN AN INTERESTING SET OF
DISCUSSIONS BECAUSE ONE OF THE
THINGS THAT IS REALLY CRITICAL
IS HIGH VALUE TO WHOM?
AND WHAT ARE SUSTAINABILITY
ISSUE THOSE ARE GOING ON AND
THEY'RE VERY INTERESTING AND
EXTREME LOW IMPORTANT FOR ALL OF
OUR RESEARCH.
WE STARTED, AS I MENTIONED
EARLIER, THERE ARE A NUMBER OF
OTHER AREAS OF RESEARCH BESIDES
THE CANCER IMAGING RESEARCH AND
CANCER RESEARCH ACROSS THE
COUNTRY, AND WE SUPPORT A NUMBER
OF NCI INITIATIVES AND SO, I'LL
RUN TRUE THESE PRETTY QUICKLY
AND IN THE CASE OF A NUMBER OF
THESE DIFFERENT INITIATIVES, THE
IMAGES ARE LINKS TO CLINICAL
DATA AND TISSUE DATA AND AND
MAKES DATA AND THE RADIOLOGY IS
A LINK TO ALL OF THESE AND VICE
VERSA AND SO WE THINK IT'S
REALLY AND CLINICAL BE PART OF
THESE AND WE HAVE WAYS OF
PHENOTYPING THE PATIENT THROUGH
IMAGING AND THE IMPORTANT DATA
IN THESE ANALYSIS.
IT'S IMPORTANT PART OF CLINICAL
DATA AS WELL.
IT'S IMPORTANT FOR THE IMAGING
RESEARCH COMMUNITY TO UNDERSTAND
AND GENOMIC RESULTS ARE OF
IMAGING DATA THAT'S ACQUIRED.
IN THE MOONSHOT WHICH IS WE'RE
COLLECTING ON THIS INITIATIVE
AND CLINICAL STANDARD OF CARE
AND IT WILL BE AVAILABLE
INTEGRATED DATA AND IT WILL BE
REALLY IMPORTANT BUT THE FOLKS
IN THE MOONSHOT PROJECT ARE
EQUALLY EXCITED AND WANT TO LET
EVERYBODY KNOW THAT THIS IS THE
FIRST TIME BEEN DATA AND AND DUE
TO THE FACT WE NEEDED TO HAVE A
CLINICAL NETWORK ACROSS THESE
INSTITUTIONS SO THIS IS A
SIGNIFICANT AND THE ABILITY TO
INTEGRATE A CLINICAL DATA WITH
GINO MAKING ANALYSIS.
IN THE ACTIVE SERVICE COMMUNITY
IN VETERANS.
NEXT SLIDE.
WE COLLECT STANDARD OF CARE
IMAGES ACROSS THE COMMUNITY
THROUGH ENCORE IN THE CANCER
MOON SHOT BIOBANK WHERE THE
IMAGES ARE CONNECTOR FOR ALL THE
THE DATA.
IN CLINICAL TRIALS WE'VE BEEN
HAVING A PRESSURE TO INCLUDE
THIS STANDARD OF CARE IMAGING
ASSOCIATED WITH CLINICAL TRIALS
AND SO THESE ARE BEING CURATED,
DEIDENTIFIED AS THE CLINICAL
TRIALS PERMIT AND WE HAVE A LONG
LIST WHERE WE'RE -- AVAILABLE
FOR CLINICAL TRIAL RESEARCHERS
AS WELL.
NEXT SLIDE.
THE DATA COMMENTS HAS COME
ON-LINE RECENTLY AND WE HAVE
HOSTED THE FIRST SET OF IMAGES
FOR CANINE KUMMORS THAT HAPPENS
TO BE THIS ONE OF THE DATA SET
WE'RE EXCITED TO BE HOSTING A
DATA FROM OTHER SPECIES AND WE
ALSO HAVE A NUMBER OF MODEL
IMAGE DATASETS OF INTEREST TO BE
LINKED WITH OTHER BIOLOGICAL
DATA ON THE ANIMAL MODELS SO WE
ALSO HAVE MIRRORING IMAGE
DATASETS AS WELL.
NEXT SLIDE.
WHEN THE COVID EPIDEMIC BEGAN,
WE WERE CONTACTED BY
INVESTIGATORS IN THE CLINICAL
CENTER IF WE COULD PROVIDE ANY
HELP OR ASSISTANCE TO COLLECT
FOR COLLECTING IMAGES OF
PATIENTS WITH COVID AND WE HAD
THE OPPORTUNITY AND THE
BANDWIDTH TO DO THIS AND PROVIDE
ASSISTANCE SO WHER WE WERE PLEASED TO DO
THAT AND USE OUR EXPERTISE IN
IMAGE COLLECTION FROM A NUMBER
OF DIFFERENT SOURCES AND PUTTING
THEM INTO USEABLE DATASETS AND
THESE CAME IN FROM AROUND THE
WORLD.
OUR GOAL WAS TO MAKE AVAILABLE
THE IMAGES AND THE APPEARANCES
OF OF WHAT COVID LOOK LIKE AND
WHETHER THROUGH CHESS FILMS
THROUGHOUT THE APPEARANCES OF
THE DISEASE THROUGHOUT ITS PHASE
AND SO WE HOSTED THOSE AND THESE
LATE ARLATER ON WERE THE FIRST USE CASE
FOR THE DEVELOPMENT AND CREATION
OF THE NEW MEDICAL IMAGING DATA
RESOURCE CENTER WHICH STARTED UP
AT NIBIB SO WE WERE PLEASED TO
HAVE THE ABILITY TO MOVE QUICKLY
TO HOST THESE DATASETS AND HAND
THEM OVER AND USE THEM AS THE
EXAMPLES OF HOW THE NIBIB
ARCHIVE WE SOURCE COULD GET
STARTED.
THE IMAGES ARE REALLY QUITE
DRAMATIC AND SOME OF THE
INVESTIGATORS HAVE BEGUN USING
IMAGE ANALYSIS TO SORT OUT LUNG
CHANGES FROM COVID VERSUS THE
OTHER EXISTING LUNG DISEASE IN A
PATIENT.
IMAGES ARE COMPELLING.
WE HAVE BEEN SUPPORTING THE
CANCER CHILDHOOD CANCER DATA
INITIATIVE AND IN THAT LIST OF
CLINICAL TRIALS IN A COUPLE
SLIDES AGO, THE FIRST SEVEN
DATASETS FROM CLINICAL TRIALS
THAT WERE COLLECTED AND HOSTED
BY THE TCIA CAME FROM CLINICAL
TRIALS AND CHILDREN AND THERE
ARE FOUR ASSETS OF THE CURATION
WITH THREE MORE IN THE WORKS
RIGHT NOW AND ONE OF THEM IS
INCLUDED A COMMUNITY AND DATA
SET.
WE HAVE THE DATA CATALOG FOLKS
TO MAKE SURE THESE DATASETS ARE
DISCOVERABLE FOR THE
INVESTIGATORS.
>>> AND OF COURSE, ARTIFICIAL
INTELLIGENCE WHICH EVERYBODY IS
TALKING ABOUT THESE DAYS, WE
HAVE STARTED ANOTHER CONTRACT
WHERE THE CLINICAL TRIALS IMAGED
DATA WE HAVE WERE TAKING IT IN
HAVING THE CONTRACTORS IDENTIFY
THE TUMOR IN IT AND FOR FOLKS TO
USE WHO MAY OR MAY NOT BE
FAMILIAR WITH IT AND HAVE LOTS
OF ALGORITHMS AND IDEAS THEY
WANT TO APPLY TO DIFFERENT TYPES
OF ANALYSIS AND WE'VE ALSO
CREATED LINKS TO THE AMERICAN
COLLEGE OF RAID 08 GEE AND MAJOR
MEDICAL IMAGING AI PLATFORMS AND
THEN OF COURSE AI FOCUSED
CHALLENGE COMPETITIONS AND WE'RE
OFTEN THE PEOPLE WHO COME THE
CLOSEST TO ACHIEVING THE BEST
RESULTS ARE PEOPLE OUTSIDE THE
MEDICAL IMAGING COMMUNITY AND
IT'S ALWAYS VERY INTERESTING TO
SEE WHAT THEY COME UP WITH FOR
THEIR SOLUTIONS.
I WANT TODAY TALK ABOUT THE ROLE
OF THE TCIA IN THE IMAGING DATA
COMMENTS.
HERE IS A PICTURE OF THE CANCER
RESEARCH DATA COMMENTS.
THE IMAGING DATA COMMENTS IS THE
NEWEST ONE TO COME ON-LINE AND
IT'S IN YEAR THREE NOW OF THAT
CONTRACT AND THE FIRST DATA SET
THAT WAS INGESTED INTO IT
BECAUSE THE TZIA.
THE TZIA WILL FUNCTION AS A
INPUT NODE FOR DEIDENTIFICATION,
DOCUMENTATION, AND THIS ALSO IS
GOING TO BE CONTINUING TO
FUNCTION AS A PLACE WHERE WE
INGEST DIFFERENT TYPES OF IMAGES
FROM NEW MODALITIES OR
MODALITIES THAT CREATE IMAGE
DATA WHETHER IT'S HISS TOLL HISTOLOGY,
DATA OR CLINICAL IMAGING DATA OR
PHOTOGRAPHIC DATA AND ANY TYPE
OF IMAGE DATA IN LOW RESOURCE
SETTINGS AND OTHER TYPES OF NEW
TECHNOLOGIES THAT ARE EMERGING.
SO, WHAT IS THE DIFFERENCE
BETWEEN THE TWO?
THE PUBLIC COLLECTIONS ON THE
TCIA ARE MIRRORED IN THE IMAGING
DATA COMMENTS BUT THE IMAGING
DATA COMMENTS ARE SET UP FOR
FOLKS WHO WANT TO WORK IN CLOUD
BASED ENVIRONMENTS AND SO THAT'S
WHAT THAT HOSTING IN THOSE
FUNCTIONALITIES ARE FOR AND THE
TCIA EVOLVING AS A PLACE WHERE
WE CONTINUE TO EXPLORE THE
VARIETY OF METADATA AND IMAGE
ANALYSIS AND NEW DATA TYPES FROM
IMAGES TO PRESENT TO THE
COMMUNITY TO SHOW THEM WHAT THEY
LOOK LIKE AND WHAT THEIR
POSSIBILITIES ARE AND HOST
ENOUGH OF THEM TO ENCOURAGE NEW
RESEARCH.
AND WITH THAT, I WOULD LIKE TO
GO TO MY LAST SLIDE AND THANK
EVERYONE FOR YOUR ATTENTION AND
ALL THE FOLKS INVOLVED TO HELP
KEEP THIS ARCHIVE ALIVE AND THIS
FUNCTION GOING AND BROUGHT IT TO
THE LEVEL OF SUCCESS THAT IT IS
TODAY.
THANK YOU, VERY MUCH.
>> THANK YOU, VERY MUCH.
THIS IS REALLY IMPRESSIVE.
>> THANK YOU.
>> VERY EXCITING.
VERY IMPRESSIVE.
SO, WE HAVE TIME FOR SOME
QUESTIONS.
>> HI, THIS IS LINCOLN STEIN AND
I HAVE A QUICK QUESTION ABOUT
TCIA AND AI.
ARE EITHER THE TCIA OR THE
IMAGING COMMONS, ARE THEY
PLANNING TO SUPPORT FEDERATED
MACHINE LEARNING?
>> SURE, TO THE EXTENT WE HAVE
THAT CAPABILITY.
IT DEPENDS ON THOSE
REQUIREMENTS.
>> IT'S ON PROMISE COMPUTE THAT
WOULD ALLOW MACHINE LEARNING
ALGORITHMS.
>> THAT'S PROBABLY GOING TO BE
MORE OF A FUNCTION OF THE
IMAGING DATA COMMONS BECAUSE
THAT WILL BE BULK DATA, LARGE
DATASETS, AND COMPUTING IN THE
CLOUD.
SO PROBABLY LESS SO IN THE TCIA
BUT IF IT'S COMING IN THROUGH
THE TCIA IT WILL BE AVAILABLE IN
THE IDC FOR THAT TYPE OF
ACTIVITIES SO THAT'S HOW WE
ENVISION IT AT THIS TIME.
>> WHY IS THAT BETTER?
WHY IS THAT USEFUL?
>> FEDERATED AI?
>> OH, THE MAIN REASON WOULD BE
IT AVOIDS THE NEED TO DOWNLOAD
LARGE DATASETS.
I DON'T THE RESEARCHERS LOCAL
COMPUTER SYSTEM AND FEDERATED
MACHINE LEARNING ALSO ALLOWS ONE
TO CREATE NETWORKS OF DATABASE
THAT'S HAVE THE SAME FEDERATED
SOFTWARE INSTALLED AND THE
LEARNING TASK CAN RUN ACROSS ALL
OF THEM WITHOUT HAVING MASSIVE
DATA TRANSFER.
>> WE TAKE THE TOOLS TO THE
DATA.
>> ULTIMATELY, IT REDUCES THE
NEED TO DEIDENTIFY AND SCRUB
IDENTIFYING INFORMATION FROM THE
IMAGES BECAUSE THE ALGORITHM
CANS WRITTEN JUST NOT TO
RETRIEVE THAT INFORMATION SO
IT'S GOT SOME ADVANTAGES.
>> THANK YOU, I HAVE TO PUSH ALL
THESE BUTTONS.
I REALLY, THIS IS SUPER COOL.
I WILL ECHO WHAT OTHER PEOPLE
HAVE SAID.
NO WONDER YOU ARE A VALUABLE AND
RESOURCE FOR NIH.
AWESOME.
KUDOS TO EVERYBODY.
I WANTED TO UNPACK JUST A BIT
ABOUT YOUR USERS.
BECAUSE, I BELIEVE YOU SAID YOU
HAVE 20,000 USERS A MONTH?
CAN YOU DESCRIBE THE SUB
CATEGORIES OF THOSE USERS?
AND I GUESS, IMPLICIT IN THERE
ARE YOU GETTING THE USERS YOU
WANT?
>> WELL, YOU KNOW, THAT'S THE --
WE TALK ABOUT THIS A LOT.
SHOULD WE KNOW WHO THESE PEOPLE
ARE?
DO WE CARE?
WHAT IS IMPORTANT?
SO, OF COURSE WE HOST THIS DATA
FOR THE IMAGING COMMUNITY AND
IMAGING RESEARCH BECAUSE IMAGING
RESEARCH IS REALLY CRITICAL AND
IMPORTANT TO ALL OF CANCER
RESEARCH.
ON ITS OWN AND AS AN IMPORTANT
ASPECT OF PROVIDING DATA FOR
INTEGRATION AND HYPOTHESIS
GENERATION AND I EMPHASIZE THAT
ALL THE TIME.
IT'S IMPORTANT TO THE IMAGING
COMMUNITY, RIGHT.
IT'S IMPORTANT TO THE IMAGING
COMMUNITY AND THE PATHOLOGY
COMMUNITY NOW IN THE PATH OMICS
COMMUNITY AND TO HAVE THIS DATA
TO ANALYZE AND INTEGRATE.
AND SO IT'S OBVIOUSLY VERY
IMPORTANT TO THESE FOLKSES WELL.
BUT THERE'S ANOTHER GROUP THAT
WE CAN ONLY TELL THROUGH
PUBLICATIONS, WE DON'T ASK
PEOPLE TO IDENTIFY THEMSELVES
WHEN THEY ACCESS THIS SITE.
WE DO KNOW THAT THERE'S LOTS AND
LOTS OF FOLKS IN TRAINING AND
POSTDOCS AND PEOPLE DOING NEW
APPLICATIONS AND NEW IDEAS AS
WELL AS PEOPLE IN THE WHO WANT
TO BE INVOLVED IN THE COMPUTING
COMMUNITY SO WANT TO SEE WHAT
THESE IMAGES AND DATA LOOKS
LIKE.
A LOT OF TIMES THEY WANT TO SEE
WHAT THESE THINGS LOOK LIKE.
LIKE THE BIG CORPORATIONS THAT
COME UP WITH HARDWARE AND
BACKBONE-TYPE SOFTWARE ARE
INTERESTED IN THESE DATASETS TO
SEE ABOUT WHAT THE DATA LOOKS
LIKE.
HOUR HOPE IS THEY WOULD GET
INTERESTED IN CANCER RESEARCH
AND HELP US CURE CANCER PATIENTS
AND PREVENT IT.
>> JUST ONE OTHER COMMENT AS A
FOLLOW-UP, OTHER ORGANIZATION
THAT'S HAVE THESE CORE
FACILITIES, SOMETIMES CREATE
MINI GRANTS.
I MEAN, THEY'RE NOT A LOT OF
MONEY.
THE INTENTION IS TO PROVIDE THAT
LITTLE BIT OF A CAR O A CARROT SO THE
PERSON WILL USE THE GRANT AND
GET THE DATA SET.
SOMETHING TO THINK ABOUT BECAUSE
YOU CLEARLY IT MAY TAKE A JUDGE
AND YOU WANT ACCESSING AND USING
THE DATA.
IT WOULDN'T BE VERY EXPENSIVE TO
GET A FIRE LIT UNDER SOMEONE AND
WE AGREE WELL THANK YOU VERY
MUCH.
IT'S A GOOD IDEA.
I'LL TAKE IT TO THE GROUP.
>> Dr. COUSINS.
>> CONGRATULATIONS AND FROM MY
POINT OF VIEW AND I WOULD SEE
THIS TO TCG A AND THE BREADTH TO
WHICH WE RELY UPON TCGA THIS
WILL BE THAT KIND OF A THINKING
FORWARD, WITHIN THE RESEARCH
COMMUNITY AND THE TRANCATION AND
SPILLING INTO THE CLINICAL
COMMUNITY WE'RE ALL VERY
INTEREST IN CELLULAR RESPONSE TO
THERAPY AND TO RESPONSE AND
RESISTANCE MECHANISMS POST
THERAPY TO WHAT DEGREE COULD
THIS BE A PLATFORM FOR UP LOAD
AND EVALUATIONS AND LARGER
COHORT MINING FOR KODAK DATASETS
AND IMMUNE' FLUORESCENCE
DATASETS, MULTI PLEX DATASETS OF
CLINICAL SAMPLES AND MOUSE
MODELS AND WE'RE LOOKING AT SEM
YOU LAR AND SPECIAL SYSTEMS.
A MAJOR COMPONENT IS THE H10.
>> SO, LET ME UP MY MICROPHONE.
I DON'T HAVE PROBLEMS.
PEOPLE HEARING ME BECAUSE I'M A
YELLER.
MAYBE THAT WILL HELP.
[LAUGHTER]
>> YES, AND YOU ARE TOUCHING ON
IMPORTANT POINTS.
THE H10 ORGANIZATION HAS ITS OWN
DATA COLLECTION AND ARCHIVES AND
A LOT OF THAT IS IMAGE-BASED
DATA OF COURSE.
THE MULTI PLEX MATERIALS AND --
>> WE'RE A PART OF THAT GROUP.
I DID RUN THAT.
>> SO, THE WAY I LOOK AT IT, THE
MOST IMPORTANT THING THAT THAT
DATA IS HOSTED AND AVAILABLE.
AND IT CAN BE, WE HAVE A
MECHANISMS IN PLACE FOR IT TO BE
AND INTERCONNECTED.
I THINK THAT SO WHO DOES IT AND
IT ISN'T THE POINT AND IT'S ONE
OF THE CURATION INPUTS FOR THE
IMAGING DATA COMMENTS.
AND SO A LOT OF THAT TIME AND
THAT FRAMEWORK SIN VISIONED TO
FUNCTION IS FOR DATA TO COME
INTO THAT IN THROUGH THE CANCER
RESEARCH AND SO HOW DOES THE
TEAM TCIA PLAY A ROLE AND
HOSTING LIKE I MENTIONED AND
DIFFERENT DATA TIMES AND HAVE
OUR GUYS FIGURE OUT AND WHAT
THESE CONSIST OF AND WHAT YOU
HAVE TO DO AND HOST THEM SO I
WOULD LIKE US TO CONTINUE
REACHING OUT AND EXPLORING WHAT
THESE DATA TYPES LOOK LIKE AND
TO LET PEOPLE KNOW THAT THEY'RE
EXTREMELY IMPORTANT AND THEY
SHOULD BE AVAILABLE FOR
INTEGRATIVE RESEARCH AND THAT
REGARD, I'VE GONE ON RECORD IN A
NUMBER OF DIFFERENT PLACES
SAYING AN IMAGE DATA IS IMAGE
DATA AND IT DOESN'T, AND THE
HISS TO BE IMMUNO FLUORESCENCE
DATA SPECIAL AND IMAGE DATA IS
IMAGE DATA AND WE HAVE A NUMBER
OF DIFFERENT WAYS TO INGEST THAT
DATA NOW AND IN THE INFORMATION
STRUCTURES AT THE NCI AND I
THINK A LOT OF THEM THROUGH THE
CANCER RESEARCH DATA COMMONS
THEY WILL BE INTERCONNECTED AND
IT'S BEING WORKED OUT ALL THE
TIME.
SO, YES, I THINK WE'RE DOING WE
HAVE PLANS AND WE'LL UNDERSTAND
AND WE'LL DO THAT.
THANK YOU.
>> WONDERFUL.
THANK YOU.
>> THANK YOU.
>> LINDA, WE ARE RUNNING OUT OF
TIME BUT A VERY QUICK QUESTION
OR COMMENT.
>> IT SHOULD BE QUICK.
SO IT WAS MENTIONED THE ANALOGY
TO THE TCGA AND I WONDER IF
THERE'S A PLAN IN PLACE ABOUT
INTEGRATING THIS WITH SPACIAL
(INAUDIBLE) AND ALL THE THINGS
COMING WHERE THERE WILL BE
SEQUENCING DATA WITH THE SPACIAL
COMPONENT AS WELL?
>> THAT WOULD BE ONCE AGAIN A
CHALLENGE OF THE ROLE OF THE
CANCER RESEARCH DATA COMMENTS
WHETHER IT COMES IN THROUGH ANY
OF OUR DIFFERENT CURATION.
THEY SHOULD COME IN THAT WAY AND
THEY'RE AVAILABLE AND
INTEGRATION.
THEY COME IN AS A SEPARATE NODE
THROUGH THE TCGA AND WHETHER WE
TAKE THEM IN OR THEY'RE SET UP
AS A SEPARATE CURIOUS AND THAT
IS WHAT IS ENVISIONED.
IMAGING DATA IS REALLY, REALLY
RICH.
THE STATISTICIANSES LOVE IT.
>> YOU'VE CONVINCED US.
[LAUGHTER]
>> W. THANK YOU SO MUCH YOUR
ATTENTION AND FANTASTIC
QUESTIONS.
>> THANK YOU.
>> IT'S BEEN AN HONOR TO CHAT
WITH YOU TODAY.
>> WE'RE DELIGHTED TO HAVE YOU
HERE.
WE'RE AT THE BREAK POINT SO --
>> ACTUALLY I HAVE A QUESTION
COMING FROM Dr. TONY
(INAUDIBLE) WITH AN OFFER TO
FOLLOW-UP WITH SOME AN EYESES
FROM SOMEONE.
>> I WAS DRINKED TO LINCOLN IF
YOU HAD ANY QUESTIONS.
>> YOU ARE THERE.
DID I SAY THE RIGHT STUFF?
>> ABSOLUTELY.
>> I TRIED TO ADD IN THE CHAT.
>> THANK YOU, TONY, THAT'S
GREAT.
>> THAT WAS GREAT, THANK YOU.
>> SO, NOW I'LL SHOULD LEAVE
EXCEPT FOR THE MEMBERS AND THE
NCI STAFF AROUND OUR VIRTUAL
TABLE SO THAT THE COMMITTEE CAN
HAVE AN ADMINISTRATIVE SESSION.
SO, IF YOU ARE AROUND THIS
VIRTUAL TABLE, PLEASE DON'T
DISCONNECT.
WE WILL BE MOVED TO A SECURE
ROOM.
EVERYONE ELSE WILL TAKE A
25-MINUTE BREAK AND WE'LL RESUME
AT 3:00, HOPEFULLY.
AND THEN THOSE AROUND THE TABLE,
WE CAN EITHER TAKE A FIVE-MINUTE
BREAK RIGHT NOW OR WE CAN JUST
GO FORWARD.
AND MAYBE TAKE A BREAK AT THE
END?
WHAT'S THE PLEASURE OF THE
COMMITTEE?
>> DO YOU WANT TO JUST GO
FORWARD?
EVERYBODY GOOD TO GO?
>> OK.
ALL RIGHT.
SO SOMEONE GOING TO MOVE US INTO
THE VIRTUAL.
>> EVERYONE WILL BE MOVED.
>> OK.
>> CANDICE, WE WON'T REJOIN AT 2:55
>> WHO WILL GIVE US AN
UPDATE ON THE AWARENESS
CAMPAIGN.
>> IT'S GREAT TO SEE YOU, I
THINK SOME OF THE MEMBERS OF
FNLAC KNOW THE NEW HISTORY HERE
AND SOME OF THE NEW MEMBERS KNOW
ABOUT THIS.
WE'VE TALKED A LOT ABOUT
ENHANCING THAT AND NOT A LOT OF
PEOPLE KNOW THAT ABOUT, FOR LOTS
OF REASONS, NONE OF WHICH IS WE
ARE IN THE PROCESS OF
RECOMPETING THE AWARD FOR
FREDERICK NATIONAL LAB AND WE
WANT A GREAT POOL OF OFFERS BUT
WE ALSO WANT THE EXTRAMURAL
SCIENTIFIC COMMUNITY TO
UNDERSTAND THE IMPORTANCE OF
FREDERICK NATIONAL LAB AND THE
VITAL ROLE AT NCI'S RESPONSE TO
SCIENCE, SO WE HAVE PRESENTED
MATERIALS IN THE PAST AND GOTTEN
FEEDBACK FROM FNLAC AND WE
DECIDED WE WANTED TO DO SOME
RESEARCH ON THE TOPIC AND HELP
INFORM OUR EFFORTS HERE AND SO
THAT'S WHAT OUR RICH AND NANCY
WILL PRESENT.
>> THANKS FOR THE OVERVIEW.
>> RICH, I DON'T SEE THAT
NANCY'S JOINED EVEN THOUGH SHE
TOLD ME SHE HAS, SO YOU MAY NEED
TO STEP IN.
>> OKAY, SOUNDS FINE, I WILL
JUST HOP IN AND WE WILL SEE IF
NANCY'S ABLE TO JOIN US.
THANKS SO MUCH FOR GIVING US A
CHANCE TO TALK TO YOU THIS
AFTERNOON.
WE WANTED TO PROVIDE YOU AS NED
SHARPLESS SAID AN UPDATE ON
WHERE WE ARE WITH THE AWARENESS
CAMPAIGN FOR THE FREDERICK
NATIONAL LAB.
WE FIRST ANNOUNCED THESE PLANS
TO EMBARK O A CAMPAIGN IN
FEBRUARY OF 2021, WHEN NANCY
SPOKE TO THIS GROUP EMPLOY SHE
DISCUSSED THE GOAL OF INCREASING
AWARENESS AND USE OF THE LAB'S
SERVICES AND RESOURCES AMONG
EXTRAMURAL SCIENTISTS AT THE
SAME TIME INVOLVING MESSAGING
WITH THE WAY WE DESCRIBE THE
MISSION OF THE LAB EVERY,
SCIENTISTS, POLICY MAKERS AND
NCI STAFF SO WE CAN BETTER
APPRECIATE AND UNDERSTAND THE
FNLCR'S VALUE.
SO NEXT SLIDE, PLEASE.
SINCE THEN,--IS THERE SOMETHING
BEFORE THIS, I'M SORRY?
OKAY, I WILL TALK IT THROUGH,
SINCE THEN WE'VE DONE A NUMBER
OF ACTIVITIES TO LAY THE FOUND
AITIONZ FOR INCREASING AWARENESS
OF THE LAB.
IN APRIL 2021, THE OFFICE OF
COMMUNICATIONS AND PUBLIC
LIAISON WORKING CLOSELY WITH THE
STAFF OF THE NCI OFFICE OF
SCIENTIFIC OPERATIONS IN
FREDERICK, PRESENTED THE LAB TO
ORGANIZATIONS INTERESTED IN
COMPETING ON THE CONTRACT DURING
A VIRTUAL INDUSTRY DAY.
WE OPENED INDUSTRY DAY WITH A
NEW VIDEO THAT FEATURED
DR. SHARPLESS AND DR. FAUCI,
TALKING ABOUT THE HISTORY AND
CONTRIBUTIONS OF THE LAB, THAT
WE HAVE SINCE--NCI'S WEBSITE.
WE WORKED WITH THE NFLCR STAFF
OF THE REVAMP OF THE FNLCR
WEBSITE TO MAKE IT MORE USER
FRIENDLY.
WE UPDATED THE MEDIA GUIDELINES
AND CODIFIED THE MEDIA
GUIDELINES FOR THE FNLCR THAT
RELATE TO EVERYTHING FROM HOW IT
TALKED TO THE MEDIA AND WHEN TO
RELATIONS WITH THE ARMY AND WE
WERE ACTIVE IN HIGHLIGHTING THE
LAB IN SEVERAL STORIES
THROUGHOUT THE NCI 50
COMMEMORATION.
SO ALL OF THIS HELPED LAY A
FOUNDATION FOR THE CAMPAIGN AND
I'M SPEAKING HERE TODAY ON
BEHALF OF AN AWFUL LOT OF PEOPLE
BESIDES MYSELF AND NONE MORE
REPRESENTATIVE OF MY WORK THAN
MY COLLEAGUE TUA [INDISCERNIBLE]
WHO WAS THE GLUE TAKEN--THEY PUT
THIS TOGETHER AND WORKED ABOVE
AND BEYOND THE CALL SO THIS IS
VERY MUCH A WORK IN PROGRESS AS
WE CONTINUE TO GATHER DATA AND
PERSPECTIVES BUT IT'S A GREAT
CHANCE TO TELL YOU WHERE WE ARE.
SO WE SET UP TO FOLLOW 2 PRONGS
AS YOU SEE HERE.
FIRST TO GAUGE THE UNDERSTANDING
OF THE FNLCR AND THE UTILIZATION
OF ITS RESOURCES THAT ARE
AVAILABLE TO THE EXTRAMURAL
COMMUNITY.
AND SECOND, TO LOOK AT THE
OVERALL AWARENESS AND VISIBILITY
OF THE NATIONAL LAB.
SO PERHAPS THE MOST OBVIOUS
THING I CAN TELL YOU THAT WE
WERE REMINDED OF AND THAT'S NOT
A SURPRISE TO AN, VU HERE IS
THAT THE FREDERICK NATIONAL LAB
IS COMPLEX.
IN MY 17 YEARS, AT NCI, IT'S
ALWAYS BEEN A STRUGGLE, I FOUND
TO EXPLAIN WHAT GOES ON THERE
AND EVEN HAVING BEEN LOCATED IN
FREDERICK FOR SEVERAL YEARS, IT
WAS THEN AND STILL IS FOR ME, A
DIFFICULT PUZZLE.
BUT OUR THOUGHTS AND
RECOMMENDATIONS ARE SPLIT
BETWEEN THESE 2 AREAS.
WITH THE FIRST BEING NEARER TERM
GOALS.
WAYS NCI CAN HIGHLIGHT SERVICES
AND LABORATORIES THROUGH THE
EXTRAMURAL COMMUNITY AND THE
SECOND CONSISTING OF THINGS THAT
WE RECOMMEND BE PUT INTO PLACE
OVER LONGER PERIOD.
WE APPROACH THIS THROUGH
ESSENTIALLY 3 COMPONENTS.
NEXT SLIDE, PLEASE.
I'M SORRY, NEXT SLIDE, PLEASE.
THAT'S WHERE THAT WENT.
SO THERE WAS AN ANALYSIS OF
RESOURCE ALLOCATION THAT WAS
CONDUCT BIDE NCI'S ANALYTICS AND
AUDIENCE RESEARCH BRANCH IN THE
OFFICE OF COMMUNICATIONS AND
PUBLIC LIAISON.
THERE WAS A SURVEY OF EXTRAMURAL
SCIENTISTS, WHICH IS LATED TO
BEGIN SHORTLY, THAT WILL HELP US
UNDERSTAND WHAT A LARGE NUMBER
OF PRIMARILY ACADEMIC SCIENTISTS
KNOW OF THE NATIONAL LAB AND HOW
WE CAN BETTER HELP THEM ACCESS
THOSE SERVICES THAT WOULD BE
AVAILABLE TO THEM.
AND FINALLY, IT WAS A SERIES OF
6 INTERVIEWS THAT TUA AND I
CONDUCTED.
SO THOSE SEARCH RESULTS FROM THE
AARB I MENTIONED WERE QUITE
HELPFUL BUT FRANKLY THEY
CONNECTED TO FACTS TO WHAT MIGHT
HAVE EXPECTED.
NEXT SLIDE, PLEASE.
THEY TOLD US THAT MOST
LABORATORIES LIMIT THEIR
PROMOTIONAL WORK TO THE FNLCR
WEBSITE AND TO A LESSER EXTENT
TO CANCER.GOV, THE NCI ESTATE.
SOME WERE MORE OPEN THAN RPGHTS
TO EXTERNAL PROMOTION WHICH AS
YOU WOULD EXPECT TENDS TO
CORRELATE WITH THEIR ABILITY AND
CAPACITY TO WORK WITH OTHERS.
SOME ARE CURRENTLY AT OR
APPROACHING CAPACITY THEY TOLD
US.
AND AS 1 MIGHT EXPECT, FNLCR
SCIENTISTS SAID THEY PAY
PARTICULAR ATTENTION TO JOURNAL
PUBLICATIONS TO LEARN ABOUT
DISCOVERIES AND INNOVATIONS, AND
TO SCIENTIFIC MEETINGS WHICH
MATTER QUITE A BIT TO THEM OF
COURSE.
IT BECAME CLEAR TO US THEN THAT
IN THE SHORTER TERM IT WOULD BE
WISE TO FOLLOW THE ADVICE OF 1
RESPECTIVE VOICE WHO TOLD US,
LOOK, DON'T OVERTHINK THIS, JUST
MAKE THE EXTRAMURAL COMMUNITY
MORE AWARE OF NOVEL SERVICES ASK
RESOURCES.
IN OTHER WORDS, ANSWER THE
QUESTION WHAT'S IN IT FOR ME.
SO SHIRT TERM WE'VE ADVISED THAT
NCI HAVE BEGUN A TARGETED
COMPAIN TO MAKE THE COMMUNITY
MORE AWARE OF NFLCR'S
CAPABILITIES THAT MAY BE
ACCESSIBLE TO THENL.
SO THOSE WE PROPOSE TO INCLUDE
IN THE INITIAL WAVE ARE, IN THE
NEXT SLIDE, PLEASE, REAGENTS AND
SERVICES SUCH AS ANTIBODIES
AVAILABLE THROUGH THE ANTIBODY
CHARACTERIZATION LABORATORY.
LAST REAGENTS, NATIONAL KRIST O
ELECTRON MICROSCOPY FACILITY,
THE NANO TECHNOLOGY
CHARACTERIZATION LABORATORY,
SERVICES PROVIDED BY THE
NATIONAL LAB FOR THE NEXT
PROGRAM, SEROLOGY SCIENCES,
SERVICES PROVIDED BY THE FNLCR
FOR THE GENOMIC DATA COMMONS AND
AS YOU HEARD DR. SHARPLESS
MENTION THE NATURAL PRODUCTS
WORK THAT IS MADE AVAILABLE
THROUGH THE FNLCR.
IMPORTANTLY, IN ADDITION TO
PROMOTIONAL ASPECTS, WE WOULD
WORK TOWARD MUCH MORE OF A
COHESIVE CLEARINGHOUSE TO ACCESS
THOSE RESOURCES ON A SINGLE PAGE
ON THE FNLCR WEBSITE.
IN THIS INITIAL PHASE FOR THIS
YEAR, WE PROPOSE A NUMBER OF
STRAIGHT FORWARD PLANS.
NEXT SLIDE, PLEASE.
THOSE WOULD INCLUDE SIMPLE VIDEO
SCREENS ACCIDENT BACKED UP BY
FACT SHEETS, AVAILABLE AT THE
NCI BOOTH AT MAJOR SCIENTIFIC
MEETINGS, HIGHLIGHTING
INDIVIDUAL RESOURCES.
A SHORT VIDEO OR SERIES OF
VIDEOS HIGHLIGHTING FNLCR'S
RESOURCES WITH ALL TOO CAUTION
THAT WE'RE NOT OVERPROMISING
WHERE CAPACITY AND/OR THE
ABILITY TO REACH OUT DOESN'T
EXIST.
A SLIDE DECK THAT HAS UNIFIED
MESSAGING ABOUT THE NATIONAL LAB
THAT MANY FOLKS ACROSS NCI AND
BEYOND CAN USE.
OPPORTUNITIES FOR IN, CI LEADERS
TO DISCUSS FREDERICK WHETHER IN
JOURNAL ARTICLES OR OPEDs,
CAREFULLY, TARGETED SOCIAL
MEDIA, ACTIVITIES THAT MAY BE
DEVELOPED TO MARK THE TENTH
ANNIVERSARY OF THE NATIONAL
LABORATORY DESIGNATION, AND
LASTLY, AND I WILL COME BACK TO
THIS, A LITTLE BIT MORE INTERNAL
PROMOTION.
SO THE 16 INDIVIDUAL INTERVIEWS
WE CONDUCTED, TENDED TO FOCUS
MORE ON THE FREDERICK NATIONAL
LABS VALUE, AND PLACE IN THE
WORLD.
UPON SO THERE WAS UNANIMITY OR
CLOSE TO IT THAT WE DO NEED TO
BOOST AWARENESS OF THE NFLCR AND
THAT ITS COMPLEXITIES MAKE THAT
DIFFICULT.
FROM THERE I HAVE TO SAY THE
RANGE OF OPINION WAS VAST.
SO TO TAKE JUST 1 AREA, NEXT
SLIDE, PLEASE.
THE DIFFERENCES WERE STARK,
ABOUT NAMES, ABBREVIATIONS AND
ACRONYMS.
SOME OF THE VOICES WE HEARD
SAID, THE NATIONAL LABORATORY
DESIGNATION IS A HUGE POINT OF
PRIDE.
OTHERS SAID THE NATIONAL LAB
DESIGNATION IS MEANING LESS
SYMBOLISM.
SOME TOLD US THE DESIGNATION AS
A FEDERALLY FUNDED RESEARCH AND
DEVELOPMENT CENTER OR FFRDC IS
WHAT REALLY MATTERS.
SOME VOICES SAID THAT FFRDC IS
GOVERNMENT JARGON AND HAS NO
PLACE OUTSIDE OF FORMAL
CONTRACTING LANGUAGE.
SOME TOLD US WE SHOULD DROP
CANCER FROM THE LAB'S NAME AND
OTHERS WERE ADAM ANT THAT IT
NEEDS TO STAY.
NOW WE WILL INCLIEWT CLUED
RECOMMENDATIONS ON THESE AND
OTHER AREAS IN OUR FINAL REPORT
BUT I DID JUST WANT TO TEE UP
WHAT SOME OF THOSE THINGS WE
HEARD WERE.
WE ALSO TRIED ON TO UNDERSTAND
SOME OF THE MISPERCEPTIONS ABOUT
FREDERICK.
MANY OF WHICH HAVE GRAINS OF
TRUTH AT LEAST TO THEM OR THAT
ARE PERHAPS ECHOES OF YEARS
PAST.
NEXT SLIDE IF YOU WOULD, PLEASE.
SO THE IMPRESSION STILL DOES
EXIST TO SOME THAT THE FNLCR IS
JUST AN EXTENSION OF THE NCI
INTRAMURAL PROGRAM THAT IT IS IN
NO WAY A RESOURCE OUTSIDE
GOVERNMENT.
NOW WE KNOW THAT NOT TO BE TRUE,
IT'S INTERESTING THAT WE HEARD
FROM SOME FNLCR SCIENTISTS THAT
THEY CONSIDER THEMSELVES
INTRAMURAL PRINCIPLE
INVESTIGATORS, NO DIFFERENT IN
RESPONSIBILITIES AND PRIVILEGES
THAN GOVERNMENT SCIENTISTS.
SOME EXPRESSED THE NOTION THAT
THE FNLCR IS SEEN ONLY AS DOING
TASK ORIENTED SCIENCE WHICH OF
COURSE IS A MISNOMER, BUT
FURTHER MORE, OTHERS WERE QUICK
TO REMIND US THAT EVEN FUNCTIONS
1 MIGHT CALL TASKINGS UPON WHICH
GROUND BREAKING INITIATIVES
STAND.
SOME COMPLAINED THAT THE MONEY
SPENT AT FREDERICK IS A DRAIN ON
THE RPG POOL, AND AS WE LEARNED
CONTINUALLY AMONG SCIENTISTS AND
FRANKLY SOMETIMES FROM MEMBERS
OF THE MEDIA, THERE'S TOO OFTEN
A PREVAILING FALSE BELIEF THAT
THE FNLCR IS FUNDED THROUGH A
MASSIVE ALLOCATION THAT IS
SLOWLY DEBITED.
AND OF COURSE THERE'S THE LONG
STANDING VIEW THAT NCI FREDERICK
IS A PART OF WHAT FORT DEATRICK
OR EVEN FOR THAT MATTER ON FORT
DEATRICK, IT'S A CHALLENGE TO
EXPLAIN BUT THE--MILITARY
INSTALLATION AND THAT IS A
DISTINCTION THAT WE BELIEVE
MATTERS.
NOW TIME DOESN'T PERMIT A
RECITATION OF EVERYTHING WE
HEARD BUT IT BECAME CLEAR THAT
THE FED RICK NATIONAL LABORATORY
IS PROHIBITIVELY DIFFICULT TO
CHARACTERIZE AS A SINGLE ENTITY.
SO AT LEAST FOR OUR
CONSIDERATION A PROMOTION, WE
NIGHT WELL BE ADVISED TO THINK
OF IT AS LABORATORIES PLURAL.
SOME ARE IN FACT INTRAMURAL.
SOME PROVIDE SERVICES AVAILABLE
TO EXTRAMURAL RESEARCHERS AND
THERE WILL BE HYBRIDS, TRAYING
TO COMMUNICATE AS A WHOLE WHAT
WILL ALWAYS BE A CHALLENGE AND
WE'RE ALWAYS GOING TO NEED TO BE
LIMITED AND SELECTIVE TO MAKE
SURE THAT WE'RE TALKING TO A
GREATER EXTENT ABOUT THINGS
WHERE THAT CAN BE A BENEFIT.
NOW CERTAINLY,--EXCUSE ME,
UPCOMING SURVEY OF EXTRAMURAL
RESEARCH AS A MENTIONED, WILL
HELP US UNDERSTAND HOW WIDELY
THE FNLCR IS KNOWN AND HOW BEST
WE CAN REACH AND INFORM THOSE
SCIENTISTS.
WE LOOK FORWARD TO INCLUDING
THOSE RESULTS IN A FINAL REPORT
AS WELL.
WE COULD LEARN TARGETED BUT
GREATER PROPOTION IN THIS ORDER
WHICH COULD HELP WITH,A WARENESS
AND APPRECIATION BY POLICY
MAKERS AND ADVOCATES ALIKE NOT
JUST AMONG SCIENTISTS BUT IN THE
CASE OF FNLCR, BRIEF
DESCRIPTIONS OR ELEVATE SPEECHES
ARE NEVER GOING TO BE EASY.
HELPING OTHERS UNDERSTAND THAT
FACILITY WILL MEAN EMBRACING ITS
COMPLEXITY WHICH IT NEEDS TO
HAVE WHEN IT PRESENTS COMPLEX
DISEASES.
SO WE URGE YOU TO WORK TO SMOOTH
SOME OF THE MONIKERS AND NAMES
OF THE LAB AND USE CONSISTENT
LANGUAGE TO DESCRIBE IT, THERE
IS ALWAYS WORK TO DO AND BETWEEN
NCI AND THE NATIONAL LAB AND
REDUCING REDUNDANCIES.
IT BEARS MENTIONING AS I SAID
BEFORE THAT WE DO NEED TO WORK
EDUCATING OUR OWN STAFF ALONG
WITH THE GREATER SCIENTIFIC
COMMUNITY BECAUSE SOMETIMES
PEOPLE INSIDE NCI DON'T HAVE A
CLEAR UNDERSTANDING OF WHAT THIS
PLACE IS AND WHAT IT DOES.
WE ALSO UNDERSTAND THAT ALL OF
THESE OUTREACH EFFORTS WHICH WE
ENUMERATE IN GREATER DETAIL WILL
BE KEY AT SOME POINT ARK
DITIONAL NATIONAL MISSIONS THAT
COME TO THE FORE.
WE'RE GOING TO NEED HELP FROM
YOU AND A LOT OF THESE EFFORTS
TO UNDERSTAND AND TO EXPLAIN.
WHAT I WANTED TO DO IS TO LEAVE
YOU THOUGH WITH A FEW THOUGHTS
THAT I THINK WRAP UP SOME OF THE
REASONS FOR THIS EFFORT.
WE ASKED MANY OF OUR INTERVIEW
SUBJECTS TO SUM UP WHAT THEY
VALUE MOST ABOUT THE FREDERICK
NATIONAL LABORATORY.
HERE ARE JUST A FEW OF THOSE
THOUGHTS.
ONE TOLD US, IT'S A BIG PLACE TO
DO CANCER SCIENCE WITH
CAPABILITIES YOU CAN'T FIND
ANYWHERE ELSE.
ONE SAID, THE FNLCR FILLS THE
BREECH AND TACKLES ISSUES THAT
ACADEMIC INSTITUTIONS AND
BIOMEDICAL COMPANIES CANNOT.
ANOTHER DESCRIBED IT AS SAFE
HARBOR FOR DATA AND
REPOSITORIES, WHERE EVERYTHING
IS IN THE PUBLIC DOMAIN AND
SERVES THE PUBLIC INTEREST, THE
COUNTRY AND THE WORLD.
ONE REMINDED US THAT FNLCR IS
NOT JUST FANCY EQUIPMENT BUT
HIGHLY QUALIFIED STAFF WITH HIGH
LEVELS OF EXPERTISE WHO MAKE A
DIFFERENCE.
ANOTHER CALLED IT A NEUTRAL
PLACE FOR SCIENTISTS TO MEET, DO
CUTTING EDGE WORK AND TAKE
RISKS.
ANOTHER DESCRIBED THE RESOURCES
THAT COULD HELP YOU AND NOT
COMPETE WITH YOU.
SO NEXT SLIDE, IF YOU WOULD.
WE DO WANT TO HEAR FROM YOU
ABOUT WHERE YOU SEE THINGS TO GO
IN TERMS OF RAISING THE
VISIBILITY OF THE LAB AND AN
OPPORTUNITIES WE MAY HAVE FOR
COLLABORATION THAT HELPS US DO
THAT AND TO
TO GET THAT ENGAGEMENT
GOING OUTSIDE THE WALLS OF THE
NCI AND THE GOVERNMENT AND WITH
THAT I THANK YOU AND I'M ANXIOUS
TO HEAR YOUR THOUGHTS.
>> THANK YOU.
THANK YOU GREAT PRESENTATION,
COMMENTS, QUESTIONS.
YES, ALLISON?
AND THEN LINDA?
>> SO, COMMUNICATING WITH PEOPLE
HAS BECOME MORE DIFFICULT AS WE
ARE ALL FRAGMENTED AND EXISTING
IN BUBBLES AND EVERYTHING.
BUT WHAT----TRAINING AS BROADLY
AS POSSIBLE BECAUSE THE BEST
WAY, THE BEST AMBASSADORS FOR
FNLAC, OR FOR THE NATIONAL LAB
IS ACTUALLY EVERYONE WHO WORKS
THERE AND IF THEY GET TRAINING
MAYBE THEY WILL FEEL MORE
COMFORTABLE ACTING
AS--COMMUNICATING ON BEHALF OF
THE NATIONAL LAB.
SO AND YOU CAN EVEN GO TO THE
POINT WHERE YOU DESIGNATE
CERTAIN PEOPLE WHO ARE HAVE YOU
GOOD AT IT WHO ARE PROFICIENT AT
IT, AS AMBASSADORS OR HOWEVER
YOU WANT TO--YOU WANT TO PITCH
IT, BUT THE MORE PEOPLE YOU HAVE
IN YOUR ARSENAL WHO CAN
COMMUNICATE EFFECTIVELY AND WHO
ARE TRAINED AND GIVEN
CONFIDENCE, I THINK THE EASIER
YOUR JOB BECOMES.
>> I THINK THAT'S A GREAT POINT
AND I WANT TO LET NANCY JUMP IN
BUT I WANT TO MAKE SURE AND
MENTION THAT 1 OF THE GREATEST
AMBAR DORS WE HAVE GOING RIGHT
NOW IS CERTAINLY DR. DMITROVSKY
AND TERRIFIC SPOKES PERSON AND
HAVE ALSO A VERY, VERY FINE
WRITER!
>> YES, HE'S EXCEPTIONAL.
I AGREEN CELLS WITH YOU.
LINDA?
DR. VANDIKE.
>> I WOULD ECHO WHATTALISON SAID
AND SAY THAT THE PEOPLE ARE
GREAT AMBASSADORS AND TO PROMOTE
THEM, I THINK FOR 1 THING BY
MAKING IT EASIER FOR THEM TO GO
TO THEIR CONFERENCES AND THINGS
LIKE THAT, SOMETIMES FROM MY
UNDERSTANDING IT'S A LITTLE BIT
OF A PAPERWORK CHALLENGE FOR
SOME OF THEM BUT MORE
IMPORTANTLY, YOU DESCRIBED SO
MANY DIFFERENT MISSIONS, SOME OF
WHICH REQUIRE PROMOTIONS AND
SOME PROMOTION AND SOME DON'T,
SO, I THINK THAT THE WAY TO DO
IT, FIRST OF ALL MIGHT BE TO
DECIDE WHICH THINGS, YOU REALLY
DO WANT MORE VISIBILITY ON AND
TO BRING THOSE FORWARD BECAUSE
BEFORE--SO THE LAST MEETING WAS
MY FIRST MEETING, BUT I REMEMBER
THERE WAS DISCUSSION OF THE
WEBSITE AND I SPECIFICALLY
LOOKED AT IT WITH NEW EYES AND I
CAN'T SAY HOW IMPROVED IT IS
FROM THE PAST BECAUSE I DON'T
KNOW EXACTLY WHEN TO COMPARE TO,
BUT, YEAH, IT DEFINITELY COULD
BE SIMPLER, SO I THINK
ESPECIALLY THOSE THINGS THAT YOU
REALLY WANT TO BRING FORWARD,
FIRST DECIDING WHAT THEY ARE
MIGHT MAKE A BIG DIFFERENCE.
>> YEAH, GOOD POINT.
>> IT'S CERTAINLY, I THINK IT'S
GREAT THAT YOU FBIS ARE--THIS
CAMPAIGN I THINK IS A REALLY
GOOD 1 BECAUSE THERE ARE A LOT
PEOPLE THAT ARE JUST NOT AWARE.
ANY OTHER COMMENTS.
>> I WILL ADD I'M NANCY MURPHY,
SORRY I HAD A PROBLEM GETTING ON
AT THE BEGINNING BUT REALLY I
WAS HERE TO SET UP RICH TO TALK
ABOUT ALL OF THE FIND THATION WE
FOUND FROM TALKING TO PEOPLE UP
AT THE LAB AND WITHIN NCI
LEADERSHIP AND THE WEBSITE HAS
COME A LONG WAY.
THERE ARE 2 WEBSITES, THERE'S
FREDERICK NATIONAL LAB HAS ITS
OWN WHICH IS A PRODUCT OF LIDOS,
AND THERE IS CANCER.GOV.
THE FNLCR IS THE BIG 1, IT HAS
MOST OF THE INFORMATION YOU NEED
TO KNOW BUT AS RICH SAID, WE ARE
CAREFUL TO NOT CONTRADICT
INFORMATION TO KEEP UP WITH
THOSE 2 WEBSITES THAT ARE
TALKING ABOUT THE LAB.
BUT IT HAS COME A LONG WAY AND
IT'S COME A LONG WAY AND JUST
SIMPLIFYING AND CLARIFYING WHAT
ALL THESE PROGRAMS ARE.
I THINK BACK AT THE BEGINNING
WHEN WE--WELL, WHEN I FIRST GOT
INVOLVED IN THIS, I THINK
DR. SHARPLESS SAID, YOU KNOW I
REALLY NEED TO GET THIS STRAIGHT
TO TALK TO STAFF, EVEN ABOUT
WHERE THEY WORK AND ARE--DO THEY
IDENTIFY AS I WORK AT THE
FREDERICK NATIONAL LAB OR I WORK
AT THE NATIONAL CANCER INSTITUTE
AND I THINK THAT AMBASSADORS
IDEA OR THE CONCEPT IS TERRIFIC
I THINK EVERYBODY NEEDS IT'S
SIMPLE POINTS AND WE'RE ALL
TALKING FROM THE SAME PAGE AND
DESCRIBING THE LAB IN THE BEST
POSSIBLE WAY.
DR. SHORPLESS AND DR. FAUCI WERE
FEATURED IN A VIDEO WE DID LAST
YEAR AND THAT COMES VERY CLOSE
TO THE MESSAGES WE WANT TO GET
ACROSS, IT'S AN EXCITING PLACE,
IT HAS A RICH HISTORY, TAKES ON
BIG CHALLENGING PROJECTS TO THE
EXTENT WE CAN GET THAT MESSAGING
OUT AND VERY IMPORTANT FOR THIS,
GOING FORWARD.
>> I AGREE NANCY.
>> OKAY.
ALL RIGHT, THANKS YOU GUYS,
REALLY APPRECIATE IT.
ALWAYS LOOK FORWARD TO GETTING
AN UPDATE FROM WHAT YOU GUYS ARE
DOING.
>> THANKS SO MUCH.
SO OUR NEXT PRESENTER IS
DR. DMITROVSKY.
FNLAC OPERATIONS UPDATE.
>> GOOD AFTERNOON, DELIGHTED TO
BE WITH YOU TODAY AND SOME OF
YOUR COMPANIONS ARE JOINING US
TODAY, SO I'M GOING TO--AS WAS
JUST MENTIONED, I WILL TALK
ABOUT FNL OPERATIONS AND AN
UPDATE.
NEXT SLIDE, PLEASE.
I'VE DIVIDED MY PRESENTATION TO
4 TOPICS, FIRSTIME GOING TO
PROVIDE YOU AN UPDATE
LABORATORIES RESPONSE TO THE
PANDEMIC.
SECOND I WILL SHOW YOU HOW
THESE, THE ACTIONS THAT WE'VE
TAKEN DID NOT DISRUPT OPERATIONS
OR DELAY DEICIZIVE SCIENCE.
THIRD, I WILL DESCRIBE HOW WE
FUNCTION AS A FEDERALLY FUNDED
RESEARCH AND DEVELOPMENT FFRDC
BY HIGHLIGHTING NCI AND NIAID
PROJECTS THAT EXEMPLIFY
FEDERALLY FUNDED RESEARCH AND
DEVELOP EFFORTS ON HOW WE SHARE
OUR EXPERTISE WITH EXTRAMURAL
COMMUNITY.
AND THEN ANSWER YOUR QUESTIONS,
IT WAS A BIT OF A PUZZLE HOW
FUNDING OCCURS AND IN THIS 1
SLIDE I'M GOING TO TRY TO CONVEY
OW FUNDS OCCURS SO ALL OF YOU
ALL OF YOU ARE FAMILIAR WITH RO1
FUNDING MECHANISMS AND OF COURSE
CORE GRANT MECHANISMS, CORE
INVESTIGATOR INITIATED
COLORSHIP.
HERE'S HOW I WOULD LIKE YOU TO
THINK ABOUT TASK ORDERS, THIS IS
A WELL ORCHESTRATED
COLLABORATION, AKIN TO THAT
BETWEEN ARCHITECT AND BUILDER IN
THIS CASE BETWEEN THE GOVERNMENT
AND A CONTRACTOR.
WHERE BOTH PARTIES ARE ESSENTIAL
FOR THE WORK TO PROCEED, THE
FUNTDING MECHANISM TASK PORD FOR
VARIETIES FIRST IS WHERE THE
BENEFITS OR SERVICES ARE
OCCURRING WITH ANNUAL FUNDED
PROARPGS, WE HAVE 5 THAT
INCLUDES THE NCI LARGE TASK
ORDER IN ADDITION NONOPERATIONAL
TASK ORDERS, 103 CURRENTLY EXIST
AND THEY SPAN THE CLINICAL
SCIENTIFIC AND FACILITIES WORK
THAT WE DO.
BUT WHAT YOU MAY NOT BE FAMILIAR
WITH IS THE FACT THAT THE
FUNDING THAT COMES TO THE
FREDERICK FLAGZAL LABORATORY
FREQUENTLY THEN IS SHARED WITH
THE EXTRAMURAL CANCER SCIENCE
COMMUNITY AND THAT'S THROUGH
SUBCONTRACTING MECHANISMS SO
WHAT THE TASK ORDER IS MEANT TO
DO IS TO NOT REPLICATE WHAT GOES
ON IN THE INDUSTRY SETTING OR
THE ACADEMIC SETTING BUT TO DO
WORK THAT IS OTHERWISE NOT
READILY CONDUCTED OTHER THAN
THROUGH AN FFRDC SO THIS GIVES
GIVES
YOU A SENSE OF THE WORK THAT'S
DONE NOW.
NOW LET ME SHOW YOU ABOUT RAPID
RESPONSE, THAT'S SHOWN IN THE
NEXT SLIDE.
THIS IS TAKEN FROM OUR WORK,
INTERNATIONAL WORK WITH NONAD,
AND I WILL SHOW YOU IN A MOMENT
A VIDEO.
BUT LET ME SET THE STAGE.
WE OVERSEE THE C. H. RENNIE
HOSPITAL IN LIBERIA, SADLY THERE
WAS A FIRE THAT NEARLY DESTROYED
THE FACILITY.
LET ME SHOW YOU THE VIDEO NOW IF
YOU COULD RUN THE VIDEO.
>> A BUCKET BRIGADE ACTUALLY
PRESERVED BOTH THE RESEARCH
FACILITY AND OUR CLINICAL CARE
FACILITY, WHAT YOU ARE SEEING AN
IMAGE FROM FROM A TELEVISION
BROADCAST IN LIAISON BERNEA DEET
WRA IS SEVERAL OF OUR EMPLOYEES
WHO SAVED THE BUILDING SADLY,
AFTER THE FIRE OUTBREAK THERE
WAS A LOOTING EVENT BUT BECAUSE
OF THE PROACTIVE APPROACH THAT
WE'VE TAKEN AND THE FAMILIARITY
WE HAVE IN WORKING WITH MILITARY
AND POLITICAL UNSTABLE AREAS, WE
HAD ALREADY USE PUT IN PLACE
WIRE CUTTER RESISTANT CABLES
THAT PREVENTED ANY OF OUR
EQUIPMENT TO BE STOLEN OR
DAMAGED INCLUDING PRECIOUS
CLINICAL SAMPLES AND SO ABOUT A
WEEK AFTER THE FIRE WE WERE ABE
TO RESTORE BOTH OUR CLINICAL
CARE AND OUR RESEARCH ACTIVITIES
AS RICH HAD MENTIONED A MOMENT
AGO, I TRY TO TELL THE STORY OF
FREDERICK NATIONAL LAB AND I
PUBLISHED A SERIES OF .ARE ON
HERE TEMPTING THEM AND STAT
NEWS IN THE BALTIMORE SUN ABOUT
THE VALUE OF SUCH PUBLIC PRIVATE
PARTNERSHIPS SO THIS IS AN
INTERACTION BETWEEN NIAID,
FREDERICK NATIONAL LABORATORY,
THE LOCAL MELGT MINISTRY AND
MANY, MANY OTHER PARTNERS, THIS
IS THE KIND OF WO, THAT GOES ON
HERE, PUBLIC-PRIVATE
PARTNERSHIPS, I WILL RETURN TO
THAT POINT LATER ON, WELL THE ME
CONTINUE THEN WITH THE NEXT
SLIDE.
>> WE ARE MANDATED BY OUR
CONTRACT TO PRESERVE VETERINARY
SCIENTIFIC CLINICAL SERVICES.
SHOWN IN THIS SLIDE ARE THE
DIRECTORATES THAT ARE IN CHARGE
OF ALL OF THESE ACTIVITIES, NOT
SHOWN ARE THE OTHER DIRECTORATES
THAT ARE RESPONSIBLE FOR
FACILITIES, CUSTODIAL SERVICES
OHS SERVICES AND EOS TEAMS.
225 OF OUR STAFF NEVER LEFT THE
WORKPLACE DURING THE PANDEMIC
AND I WHAT I WANTED TO REPORT TO
YOU IS THAT WE HAD NO DISRUPTION
OF THE VITAL WORK THAT WE'RE
MANDATED TO CONDUCT.
NEXT SLIDE, PLEASE.
AS WE WORKED WITH THIS ON OUR
THIS WAS SUCH AN EXTENT THAT WE
HAD TO IMPLEMENT A NUMBER OF
DECISIVE STEPS TO PRESENT
DISRUPTION OF SERVICES, LET ME
TELL YOU ABOUT THOSE STEPS.
FIRST WE UNDERTOOK WEEKLY
EXECUTIVE LEADERSHIP TEAM
MEETINGS TO ENHANCE
COMMUNICATION AND MAKE SURE THAT
EVERY ESSENTIAL SERVICE WAS
BEING PROVIDED.
WE THEN MOVED TO SPLIT SHIFT, WE
STEPPED BACK ON ROUTINE SERVICES
SO THAT WE COULD DO VITAL
SERVICES, WE TURNED A MAXIMUM
TELEWORK, WE PRIORITIZED THE
HEALTH OF OUR TEAM AND WE USED
AN I.T. SOLUTION TO MONITOR CASE
MANAGEMENT AND THOSE AFFECTED
WITH COVID AND OF COURSE, WE
FOLLOWED ALL NIH AND CDC
GUIDELINES.
BUT I WANT YOU TO KNOW IS THAT
ALL OF THIS WORK HAPPENED
WITHOUT COMPROMISING OTHER WORK
RELATED TO CANCER AND I WILL
SHOW YOU EXAMPLES OF THAT IN A
MOMENT.
SO THIS IS HOW WE COPED WITH THE
PANDEMIC STRESSES ON OUR
COMMUNITY, NEXT SLIDE, PLEASE.
WHAT I WOULD LIKE TO TELL YOU IS
THE MIND SET WE HAVE PRACTICES
THE OPERATIONS POINT OF VIEW,
AND THAT MIND SET IS 1 OF
SERVANT LEADERSHIP.
WHAT WE HAVE IN THIS CULTURE OF
SERVICE WE DO EVERYTHING IN OUR
POWER TO REDUCE ADMINISTRATIVE
BURDEN AND WE MODEL VIGILANCE
AND PROCESS REVIEW REFINEMENT,
CONTINUOUS PROCESS IMPROVEMENT
AND I WILL GIVE YOU 1 EXAMPLE OF
THIS BOTH IN ACADEMIC CENTERS
AND ALSO AT THE NIERK H, THERE
IS A CENSUS WHERE PEOPLE ARE
LOCATED, THIS IS CALLED THE NIH
ENTERPRISE DIRECTORY AND THIS IS
WHAT DICTATES SPACE CHARGES.
SO AS IT TURNED OUT BECAUSE IT
WAS A MANUEL PROCESS, AND
BECAUSE OF DELAYS DURING THE
PANDEMIC WHAT WE UNCOVERED IT
WAS NOT UP TO DATE, WHAT DOES
THIS MEAN?
THIS PLEENS THEY WERE PAYING
2.25 MILLION A YEAR, THAT COULD
HAVE GONE TO SCIENCE THAT NOW
GOES TO SCIENCE BECAUSE WE PUT
IN PLACE A I.T. SOLUTION SO IT'S
NO LONGER DONE MANUELLY SO AT
THE SAME TIE WE RETURN A QUARTER
OF A MILLION DOLLARS, AND SO
EVERY YEAR, THE BENEFITS
CONTINUE TO ACCRUE HERE YEAR
OVER YEAR.
NEXT SLIDE, PLEASE.
WE SEEK TO HAVE THE LEANEST
POSSIBLE ADMINISTRATIVE STAFF
HERE'S THE DATA OVER THE LAST 6
YEARS NOW THE OVERALL CONTRACT
BECAUSE OF GROWING REQUESTS FOR
SCIENTIFIC THE WORK TO BE DONE,
IN LARGE PART DUE TO PANDEMIC AS
GROWN DURING THIS PERIOD BY 19%.
YET WE WERE ABLE TO CONSTRAIN
GROWTH OF OUR SCIENTIFIC STAFF
AND OUR INFRANCIS COLLINS
STRAWCTURE STAFF RESPECTIVELY BY
12.7%.
HERE'S WHAT'S NOTABLE, OUR
ADMINISTRATIVE STAFF OVER 6
YEARS DECREASED BY 6.5%.
JUST THINK FOR A MOMENT ALL THE
MONEY THAT IS SAVED AND IS
DIRECTED TOWARDS SCIENCE COMING
FIRST.
HOW DID WE DO IT.
WE DIDN'T BACK FILL SOME
POSITIONS.
WE REMOVED ROLES TO INCREASE
EFFICIENCY, WE RIGOROUSLY
IMPROVED PROCESSES AND WE ALSO
AT THE SAME TIME HAD AN
OPPORTUNITY TO ADD TO THE
DIVERSITY OF OUR LEADERSHIP
TEAM.
WHILE WE WERE RIGHTICIZING THE
ORGANIZATION OVER THE PAST 6
YEARS, WE DID SOMETHING ELSE WE
INVEST INDEED OUR STAFF, HOW SO?
JUST OVER 3 YEARS AGO, WE FORMED
A--FOR THEIR FAMILIES BECAUSE WE
REPURPOSED WELLNESS BUDGET, A
PROGRAM CALLED ORGSTRIDE, AND
THAT'S TO PROVIDE CANCER CARE
NAVIGATION SERVICES THROUGH
HOPKINS.
THIS HAS BEEN A HUGELY POPULAR
PROGRAM IN OUR COMMUNITY AND A
YEAR LATER WE DID THE SAME WITH
HOPKINS FOR DIABETES AND
PREDIABETES CONTROL AND LAST
YEAR I WAS PERSONALLY CONCERNED
OF HOW THE PANDEMIC AS A
PHYSICIAN AFFECTED THE
BEHAVIORAL HEALTH OF OUR STAFF.
WE LAUNCHED ANOTHER PROGRAM
CALLED BALANCE TO PROVIDE
NAVIGATION SERVICE THROUGH
HOPKINS FOR BEHAVIORAL HEALTH
SERVICES.
AS A PHYSICIAN, MY THOUGHT WAS
THAT THIS WOULD NOT ONLY ENHANCE
RETENTION AND RECRUITMENT BUT IT
WOULD DO SOMETHING ELSE.
I SURMISED IT WOULD REDUCE OUR
HEALTHCARE COSTS.
WELL, DID IT?
THREE YEARS AGO WE WERE IN
DEFICIT $2.5 MILLION, TODAY,
WE'RE SEEING A SURPLUS OF OF
OVER A MILLION DOLLARS, SO
WELLNESS, WORKS, NEXT SLIDE,
PLEASE YOU HAVE HEARD SEVERAL
EXCITING INITIATIVES ON SERNET
INITIATIVE, BUT YOU HAVE NOT
HEARD IS THAT WE DOCTOR TO
DEVELOP A SPACE UNDER
DR. PINTO'S LEADERSHIP THE
VACCINE AND IMMUNOLOGY AND
CANCER DIRECTORATE WILL NOW BE
PLACED IN 1 CONTIGUOUS SPACE,
WE'VE IDENTIFIED NEARLY FOURTH
FLOOR OF SPACE, IT'S OCCURRING,
THE REFURBISHMENT IS OCCURRING
IN PHASES, FIRST WE ARE
RELOCATING THOSE SCIENTISTS WHO
ARE PRESENT IN THIS SPACE TOIN
MINIMIZE THE EFFECT OF MOVE ON
THEM.
AND WE WERE ABLE TO DO THIS BY
IMPROVING A REFURBISHMENT
PROCESS BY REDUCING
REFURBISHMENT PROCESS BY 6
MONTHS, SO THIS ALLOWS THIS
INTERNET TEAM TO COME TOGETHER
BUT SAT THE SAME TIME THEIR WORK
IS CONTINUING SHOWN IN THE NEXT
SLIDE.
AS A CLINICIAN, EXCITING OUTPUTS
OF THIS TEAM, IS THAT THEY'VE
BEEN ABLE TO HARMONIZE SEROLOGY
ASSAYS SO THAT THEY CAN--SO THAT
IT'S POSSIBLE NOW TO COMPARE
RESULTS FROM DIFFERENT SEROLOGIC
STUDIES.
THIS IS A HUGE BENEFIT FOR THE
PHARMACEUTICAL INDUSTRY, FOR
FEDERAL LABORATORIES, FOR THE
SERNOTE INIT WHYATIVE AND THEIR
COLLABORATORS MULTIPLE ACADEMIC
INSTITUTIONS.
AND WE'RE REALLY EXCITED TO SEE
THIS CLINICALLY RELEVANT
RESOURCE OF SEROLOGY
STANDARDIZATION MOVE FORWARD.
>> SEVERAL YEARS AGO, WE
LAUNCHED UNDER THE LEADERSHIP OF
JIM DOROSHOW, IT WAS THE BRAIN
CHILD OF DR. SHARPLESS AND AMONG
THAT NEED, AGAIN, THAT'S
THE--THAT IS THE DRIVING PURPOSE
OF OUR WORK ASK THAT WAS TO
PROVIDE NCI THROUGH THE NCI
CAR-T-CELL REDUCTION FOR RARE
CANCERS AND PEDIATRIC CANCERS.
WE HAVE TREATED 14 PATIENTS WITH
CAR T-CELLS TARGETING CD34
CHILDHOOD AML AND IN OUR FIRST
CASE OF CHILDHOOD NEUROBLASTOMA
WOULD BE TREATED WITH A GD2
TARGETING CART-CELL SOON, WE'RE
LOOKING AHEAD TOWARDS OTHER
CANCERS TO CONSIDER LIKE
COLANGIO CARCINOMA CORRELATING
LATER THIS YEAR AND A TECHNOLOGY
BASED SYSTEM APPROACH TO
THAT--STANDARD IS, YOU KNOW THIS
IS CURRENTLY LENTI VIRUS BASED
APPROACH BUT WE HOPE TO
TRANSITION TO A CRISP CAS 9
BASED TECHNOLOGY SO REALLY
EXCITED YOU THIS IS DEVELOPED
REAR MOMENTUM AND SERVICE AS AN
UNMET NEED IN THE EXTRAMURAL
COMMUNITY.
SO NOT ONLY IS THIS WORK BEING
CONDUCTED AT THE NCI BUT A SHOT
AT MANY OTHER PEDIATRIC ONCOLOGY
CENTERS.
NEXT SLIDE, PLEASE.
SO YOU'VE HEARD ABOUT EACH OF
THESE AT THE CRYOFACILLITY AND I
WANT TO GIVE YOU AN UPDATE OF
WHERE WE STAND AND SHOW THIS AS
AN EXAMPLE OF THE FLEXIBILITY OF
A NATIONAL LAB AND ALSO THIS
RESOURCE AND EXCLUSIVELY DEVOTED
TO EXTRAMURAL SCIENTISTS.
IN THE RIGHT OF THIS POWER
POINT, YOU CAN SEE OUR CURRENT
EXTRAMURAL COLLABORATORS AND
IT'S NOTABLE TO POINT OUT THAT
IN THE FIRST 5 YEARS THERE HAVE
BEEN 119 EXTRA MIEWR AT
SCIENTISTS FROM 50--IMAGING
TECHNOLOGY THAT WE MADE
AVAILABLE THROUGH OUR CRYOEM
FACILITY.
ANOTHER SESSIONS HAVE BEEN
COMPLETED, IN TOTAL OVER 5
YEARS, 64 PUBLICATIONS, AND IN
THE LAST YEAR, ALONE, 29
PUBLICATIONS IN THE HIGHEST
YEAR, JOURNALS LIKE SCIENCE,
NATURE, NATURE, COMMUNICATION,
IN FACT WHAT YOU CAN SEE IS THAT
THE RATE OF PUBLICATIONS ARE
INCREASING SO LET'S LOOK AT THE
LOWER AND TELL US VISUALLY A
WORTHY STORY OF HOW WE PIVOTED
FOR THE PANDEMIC RESPONSE AND
COMPENSATED FOR DELAYS, IN APRIL
OF 2020, AS WE ALL EXPERIENCED
WE PAUSED ALL NONSCIENTIFIC WORK
AT NIH BUT WE WERE ABLE TO PIVOT
IN RED TO COVID RELATED PROJECTS
AND WE DID SOMETHING ELSE, WE
COMSATED ONCE THE WORK WAS
APPROVED BY THE NIESH H DIRECTOR
TO RETURN TO CANCER RELATED
PROJECTS BUT AT A HIGHER LEVEL.
OVER THE NEXT YEAR, WE HAD 3
SCHEDULE SAID REPAIRS IN EACH
CASE THERE WAS A DECLINE IN
IMAGING BUT RIGHT AFTER EACH
DECLINE THERE WAS A COMPENSATORY
INCREASE ARE AND THE SAME WAS
SEEN WITH THE OMICRON VARIANT
EXPOSURE.
SO IN AN EXAMPLE OF RAPID
RESPONSE AND FLEXIBLE RESPONSE.
LET ME SHOW YOU IN THE NEXT
SLIDE, THE PUBLICATIONS JUST IN
THE LAST YEAR.
SO KEEP IN MIND EVERY AUTHOR IS
AN EXTRAMURAL SCIENTISTS,
MULTIPLE PAPERS PUBLISHED IN
NATURE, MOLECULAR CELL, SCIENCE,
NATURE COMMUNICATION, AND THIS
IS JUST IN THE PAST YEAR.
THIS IS AN EXAMPLE OF WHAT AN
FFRDC CAN DO TO SERVE THE
EXTRAMURAL CANCER SCIENCE
COMMUNITY.
LET'S CONTINUE TO THE NEXT
SLIDE.
DR. SHARPLESS AND DR. LILLY HAVE
CITED WHAT I THINK IS A TRAIL
PLASSING PAPER IN PNAS AND I
WILL NOT RESTATE WHAT THEY SO
APTLY DESCRIBED IN THIS WORK BUT
BRING YOU ALONG WITH THE
DIFFERENT POINT THAT I WOULD
LIKE TO TAKE AWAY FROM THIS
PUBLICATION.
AND THAT IS, THIS IS A CASE
STUDY OF TEAM SCIENCE.
THIS WORK WAS THE PRODUCT OF
FREDERICK NATIONAL LAB, LAWRENCE
LIVER MORE, LOS ALAMOS, ARGON,
NATIONAL LAB RAARE TOYS, UCSF,
RPT TEAM, AND CRTP AND SAN JOSE
SNAIT.
WHAT I FIND ABOUT THIS IS THAT
IT'S BUT A START OF THE
BEGINNING.
BECAUSE NOW WE CAN BUILD ON THE
MODELS, BECAUSE THE TEAM IS IN
PLACE.
LET ME SHOW YOU 1 MORE EXAMPLE
AND THE NEXT SLIDE, THAT YOU'VE
ALREADY SEWN BUT I'M GOING TO
MAKE SOME ADDITIONAL POINTS AND
THAT IS THIS EXCITING DISCOVERY
THAT MARY CARRINGTON AND
DR. MARY CARRINGTON AND
COLLEAGUES PUBLISHED IN LANCET
IN ONCOLOGY, TO ME IT'S
ESPECIALLY TELLING BECAUSE AS
YOU ALREADY HEARD, SPECIFIC HLA
GENOTYPES CAN PREDICT RESISTANCE
TO CHECK POINT BLOCKADE, BUT ON
THE RIGHT, YOU CAN SEE, IT
DOESN'T PREDICT RESPONSE TO
STANDARD OF CARE SUCH AS VEG F
THERAPY FOR RENAL SUBCANCKER
CASES.
SO THIS HAS THE HALLMARKS OF
POTENTIAL SPECIFIC THERAPY
BIOMARKER AND I'M REAL EXCITED
TO SEE THE NEXT STAGE OF THIS
WORK.
NEXT SLIDE, PLEASE.
WHILE WE PIVOTED TOWARDS COVID,
WE ALSO WERE REQUIRED TO
CONTINUE OUR WORK WITH NIAID.
AND HERE IS THE PORTFOLIO OF THE
MOST RECENT PRODUCT
MANUFACTURING THAT OUR PILOT
PLANT AS DONE LOOKING AT THE
LEFT, YOU CAN SEE OUR HIV
TARGETING, AND NEUTRALIZING
ANTIBODY WORK REGARDING EBOLA BI
SPECIFIC AND MONOCLONAL
ANTIBODIES UNDER PRODUCTION AND
AN TREEING NANO PARTICLE MAY
ZAYIC AND INFLUENZA VACCINE WILL
BE PRODUCED AND THIS IS A
POTENTIAL UNIVERSAL FLU VACCINE
AND THEN IN THE RIGHT YOU CAN
SEE THE PRODUCTION OF A
MONOCLONAL ANTIBODY FOR MALARIA.
LET ME SHOW YOU ON THIS LAST
SLIDE THIS LAST EXAMPLE OF THE
VACCINE RESEARCH CENTER IN
CONJUNCTION WITH OUR PILOT, TEAM
PUBLISHED WHAT I THINK IS A
SEMINOLE PAPER IN THE NEW
ENGLAND JOURNAL OF MEDICINE AND
THIS WAS A MONOCLONAL STUDY FOR
THE PREVENTION OF MALARIA.
NOW I HAVE SPENT SOMETIME
TREATING MALARIA PATIENTS I WAS
A MEDICAL VOLUNTEER FOR THE
INTERNATIONAL COMMUNITY IN THE
REFUGEE CAMP AND TREATED A LOT
OF CANCERS, IT'S NOT ONLY
DEVASTATING BUT IT'S HUGELY
DEVASTATING INFECTION, IT IS A
HUGE, HUGELY CRUEL INFECTION FOR
CHILDREN.
AND THE FACT THAT THERE MAY BE A
THERAPY THAT COULD PREVEBT
MALARIA TO ME IS 1 OF THE MOST
EXCITING WORK THAT I'VE SEEN IN
YEARS IN TERMS OF MALARIA
RESEARCH AND SO THIS HAS SPAWNED
A PHASE 2 TRIAL THAT'S UNDERWAIN
AFRICA AND I'M REALLYKS SIGHTED
TO SEE HOW THIS WORK PROGRESSES,
IN THE RIGHT SIDE OF THIS POWER
POINT, CAN YOU SEE OVER THE NEXT
YEAR AND A HALF, THAT PRODUCTION
PLANS FOR VARIETY OF NEW
MANUFACTURED PRODUCTS SO LET'S
MOVE ON TO THE NEXT SLIDE,
PLEASE.
>> ETHAN, I HATE TO INTERRUPT
YOU BUT YOU DO WANT TO ALLOW
AUTOLEAST 5-10 MINUTES FOR
QUESTION, BECAUSE WE'RE SUPPOSED
TO END AT 4.
>> OH YEAH, SURE, I WILL BE ABLE
TO DO THAT.
THANK YOU FOR YOUR HELPFUL
INPUT.
SO JUST GO AHEAD AND TELL YOU
ABOUT 3 EDUCATIONAL PROGRAMS
THAT WE'VE BUILT, WE COULD GO
BACK 1 SLIDE, FIRST.
WE HAVE ACCRUED RUNNING CLINICAL
TRIALS IN ADVERSE CONDITIONS SO
WE'RE HAVING A VIRTUAL TRAINING
PROGRAM WITH CME CREDIT TO
PROVIDE US A RESOURCE TO THE
EXTRAMURAL COMMUNITY.
THE SPRBS WE HAVE TO SHARE THAT
EXPERIENCE IN CONDUCTING TRIALS
AS WE DID WITH EBOLA, NEXT
SLIDE, PLEASE.
SIMILARLY, WE WILL BE PROVIDING
TO THE EXTRAMURAL COMMUNITY AND
I URGE THE FNLAC PANEL MEMBERS
TO SOCIALIZE THIS WITHIN YOUR
INSTITUTION A 5 DAY KRIST O EM
USERS AND THAT WILL BE DIDACTIC
AND HANDS ON EXPERIENCE,
MARCH 15th THROUGH
APRIL 15th WE WILL SOLICIT
APPLICATIONS, SITE SHOWN HERE,
PLEASE ENCOURAGE THOSE IN YOUR
INSTITUTION AND SOCIALIZE IN
THOSE GENERALLY FOR TO APPLY.
THIS IS FREE OF CHARGE AND
ALMOST I JUST WANT TO TELL YOU
ABOUT 1 OTHER EDUCATIONAL
INITIATIVE AND THE NEXT SLIDE ON
FEBRUARY 11th WE WANT TO
RECOGNIZE THE INTERNATIONAL DAY
OF GIRLS AND WOMEN IN SCIENCE.
WE SEE 1 OF OUR MISSION IS TO
ENHANCE THE DIVERSITY OF THE
CANCER SCIENCE WORKFORCE.
SO A KEY NOTE SPEAKER IS
DR. CARLA WILLIAMS WHO IS THE
INTERIM DIRECTOR OF THE HOWARD
UNIVERSITY CANCER CENTER.
WE HAD A DISTINGUISHED PANEL OF
SCIENTISTS BOTH FROM FREDERICK
NATIONAL LAB, NCI AND THE U.S.
PATENT AND TRADE MARK OFFICE
THIS WOULD BE AN ANNUAL EVENT
TIELTED WOMEN AND SCIENCE SPEAK.
IT WAS VERY WELL RECEIVED.
240 REGISTRANTS FOR THIS
CONFERENCE, THE FIRST OF WHAT WE
HOPE WILL BE ANNUAL, NEXT SLIDE,
PLEASE, WHICH IS TO CONVEY THAT
WE HAVE TRIEFED TO DEVELOP A
ROBUST ACADEMIC PARTNERSHIP WITH
A NUMBER OF EXTRAMURAL
COLLABORATORS TO PROVIDE
RAINING, SEBATICLE, POST
DOCTORAL FELLOWSHIP, TRAINING
EXPERIENCES.
I WILL TELL YOU ABOUT 1, I SERVE
ON RESEARCH COUNSEL OF THE
AMERICAN CANCER SOCIETY AND AS A
PROFESSOR I WAS ASKED TO PARTNER
WITH DR. WILLIAMS TO PROVIDE
MENTORSHIP FOR THEIR TRAINEES
AND FACULTY TO ENHANCE THE
DIVERSITY OF THE WORKFORCE FOR
CANCER SCIENTISTS.
SO IN THE FINAL SLIDE.
I HAVE SOUGHT TO REVIEW HOW WE
RAPIDLY RESPOND ON TO THE
PANDEMIC THIS DID NOT DISRUPT
ANY ESSENTIAL WORK AND IT DID
NOT ENHANCE ANY OTHER EFFORTS
AND THANK YOU SO FCH YOUR
ATTENTION AND WE WELCOME ANY
QUESTIONS.
>> I THINK YOU MIGHT BE MUTED.
>> --FOR QUESTIONS I'M SORRY, SO
WHILE PEOPLE ARE THINKING, I
THOUGHT THAT WAS A VERY
INTERESTING FOR WELLNESS FOR
YOUR EMPLOYEES, WITH HOPKINS,
HOW DID YOU CHOOSE OPERATING
GLOBALLY KINS, DID YOU HAVE TO
SORT OF OPEN THIS UP FOR OR DID
YOU JUST HAVE A RELATIONSHIP
WITH THEM, I HAD A RELATIONSHIP.
>> YEAH, AND WANTED TO--SO THAT
STORY IS REALLY FASCINATING AND
THAT IS THAT THEY DECIDED TO
BUILD THIS PROGRAM IN HONOR OF
THE FORMER CANCER CENTER
DIRECTOR WHO PASSED ASHING ASHING--AWAY
FROM CANCER.
THAT WAS THE MOTIVATION >>
THAT'S VERY NICE.
>> HOW DO YOU FUND THIS, IS THIS
FUNDED THROUGH--
>> WE'RE REALLY REPURPOSING
WELLNESS BUDGET, DR. JOHNSON SO
IT'S NO TO NOMINAL COST.
WE'RE JUDGE UTV REPURPOSING
FUNDS THAT ARE ALREADY THERE.
>> IT'S REALLY, A GREAT IDEA, I
COMMEND YOU FOR THAT.
>> THANKS.
OTHER QUESTIONS FOR
DR. DMITROVSKY.
>> WHAT ABOUT YOUR ABILITY TO
KEEP GOING--PART OF WHAT YOU
WERE FOCUSED ON WAS REALLY
RESPONDING TO COVID.
BUT ACROSS THE COUNTRY AND
ACADEMIC MEDICAL CENTERS WE'RE
FACING A PIECE OF THIS GREAT
REZONING 8 HOURS NATION AND
FRANKLY I'M--REZONING 8 REZONING 8 HOURS
NATION AND I'M REALLY CONCERNED
ABOUT MY FACULTY THAT ARE REALLY
STRUGGLING EVEN THOUGH PEOPLE
ARE ACTING LIKE WE'RE DONE WITH
COVID, EVEN THOUGH COVID IS NOT
QUITE DONE WAUS AND SO WOMEN AND
FACULTY OF COLOR STRUGGLE SOIME
WONDER DID YOU SEE ANY IMPACT OF
THAT DIRECTLY ON BEING THE
SCIENTISTS OR WAS YOU KNOW IN
FACT ON STAFF, IT WAS LIKE HE
JUST KEPT ON GOING, BUT DID YOU
FEEL ANY OF THOSE ISSUES DESPITE
THE HIGH PRODUCTIVITY RATE.
I'M REALLY CONCERNED ABOUT BURN
OUT, I'M CONCERNED ABOUT THE
HIGH HOW WE CAN STRATEGY AND
FINANCIAL INNOVATION OFF A GREAT
REZONING 8 HOURS NATION.
WE HAVE SEEN A--WE HAVE SEEN A
BUMP IN PEOPLE WHO HAVE MOVED ON
TO NEW OPPORTUNITIES.
I'M ONLY GIVING YOU A FEW
EXAMPLES OF THE INVESTMENTS
WE'VE MADE IN OUR WORKFORCE,
WE'VE MADE MANY MORE AND HERE'S
AN ANYTHING FACT, EVERY 2 WEEKS
I WELCOME NEW EMPLOYEES, AND
ABOUT A THIRD OF THE NEW
EMPLOYEES ARE FORMER EMPLOYEES
SO PEOPLE HAVE TENDED TO LEAVE
HERE AND COME BACK.
SO THE FIRST THING I WANTED TO
SAY IS THAT I'M DEEPLY CONCERNED
ABOUT THE BEHAVIORAL HEALTH OF
OUR WORKFORCE AND WE HAVE BEEN
DOING MUCH IN THIS SPACE.
I THINK THAT THE CHALLENGES ARE
ONLY BEGINNING TO BE SEEN, WE'VE
SEEN IT IN THE EDUCATION REALM
BUT WE WILL SEE IT IN PLACE THAT
HAD STAFF THAT NEVER LEFT THE
WORKPLACE SO I THINK HAVING A
TONE OF CARING, GENUINE CARING,
UPON THOUGHTS.
THE OTHERS THAT I HAVE THOUGHT
TO SPECIFICALLY, YOU'RE ASKING
ABOUT DIVERSITY, SO I HAVE
SOUGHT TO SPECIFICALLY FIND
WOMEN AND MINORITIES WHO CAN BE
ELEVATED, BASED ON TALENT QUH WE
HAVE RIGHTICIZED THE
ORGANIZATION AND I HAVE DONE
THAT REPEATEDLY AND THAT IS A
REALLY GREAT RETENTION TOOL.
BUT HAVING GENUINE CARING IS
IMPORTANT.
I ALSO SEND REGULAR MESSAGES TO
OUR COMMUNITY AND PEOPLE REACH
OUT TO ME, SO I AM NOT A
DISTANCE FIGURE TO THE WORKFORCE
HERE.
>> YOU HAVE RAISED THE REALLY
IMPORTANT POINT, OUR UPTICK OF
PEOPLE LEAVING IS FAR WEST THAN
WHAT THE NATIONAL NORM IS
THOUGH.
>> THANK YOU VERY MUCH.
>> YES, I BELIEVE JOHN, YOU HAD
YOUR HAND UP.
>> YES, HI, ETHAN.
THE--I WAS I'M ENCOURAGED THAT
YOU'RE RUNNING TRAINING FOR
KRIST O EM AND THERE THE FIELD
IS TAKING OFF AND THERE'S A
CLEAR NEED FOR THAT, I'M
WONDERING ON WHAT SCALE YOUR
PLANNING TO DO THAT?
LIKE HOW OFTEN?
HOW MANY PEOPLE AT A TIME?
>> JOHN, NICE TO SEE YOU AGAIN.
WE'RE GOING TO FOCUS ON THE
FIRST YEAR'S 12 STUDENT BECAUSE
OF THE REQUIREMENTS WE HAVE
REGARDING SPACING AND SO WE'LL
SEE HOW THE FIRST YEAR GOES, WE
WANT TO DEMOCRATIZE THIS
TECHNOLOGY, I AGREE WITH YOUR
ARK SESESMENT AND SO LAWN MOWER
I--WHAT I WOULD SAY IS LET'S SEE
HOW THE FITTER YEAR GOES AND WE
WOULD NOT LIKE TO--WE WOULD TRY
TO INCREASE THE SIZE OF THE
SECOND YEAR CLASS.
>> ANYTHING ELSE FOR ETHAN?
>> YES, LINDA?
>> I DON'T ACTUALLY HAVE
SOMETHING FOR ETHAN BUT I SIMPLY
WANTED TO PUBLICLY RECANT.
SO I PEEKED--MANY OF THE
UPGRADES WERE MADE AND SO, I'M
REALLY--I'M REALLY ENTHUSIASTIC
ABOUT WHAT I SEE SIGNIFY WILL
RUN THROUGH SOME OF THE
RESOURCES BUT IT LOOKS GREAT.
>> THANK YOU SO MUCH AND MARRIAN
HACKET THAT WORKS WITH RICH
[INDISCERNIBLE] AND SO MANY ON
HIS TEAM THAT YOU HEARD ABOUT,
GIVE THE FEEDBACK TO THEM, ANY
IMPROVEMENTS THAT YOU SLEEP
APNEA AND OBESITYY THAT WE CAN
ENHANCE THE WEBSITE, WE'RE
REALLY RECEPTIVE TO THAT.
>> YOU'VE DONE A REALLY GREAT
JOB.
>> THANK YOU IT'S A TEAM EFFORT,
I'M JUST REPRESENTING A TEAM AS
YOU KNOW, IN YOUR POSITION, THIS
IS JUST CONVEYING WHAT A TEAM
DOES.
>> AND A LEADER IT'S IMPORTANT
TO BE A STRONG LEADER AND SO YOU
SHOULD BE COMMENDED, ESPECIALLY
THROUGH THESE TIMES, SO ANYONE
ELSE HAVE A COMMENT.
WE'RE KEEPING RIGHT TO OUR
SCHEDULE.
FOR THAT I WILL BE HAPPY.
[LAUGHTER]
ANY OTHER COMMENTS?
IT'S BEEN A GREAT MEETING, I
THINK.
I THINK IT'S BEEN--WE'VE ALL
LEARNED A LOT AND I--I THINK
THIS HAS BEEN A GOOD 1 AND I DO
WISH WE COULD GET BACK TOGETHER
IN PERSON, BUT WE CAN LOOK
FORWARD TO HOPEFULLY IN THE FALL
PERHAPS.
PAULA DO HAVE YOU ANY WORDS?
TO EXIT OR LODEC.
>> I DON'T HAVE [INDISCERNIBLE].
>> OKAY.
>> ALL RIGHT.
>> THANK YOU SO MUCH.
>> THANK YOU SO MUCH, JOY,
EVERYBODY, EVERYBODY THAT PUT
THIS TOGETHER, THANK YOU FOR A
GREAT MEETING AND--
>> YOU DID A GOOD JOB.
>> AND WE WILL SEE YOU LATER.
>> THANK YOU